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Iyer, Neeraj N., Ph.D., Purdue University, December 2013.  Health Care Resource 
Utilization and Expenditures in Persons with Autosomal Dominant Polycystic Kidney 
Disease.  Major Professor: Joseph Thomas III. 
The objectives of this study were to determine prevalence of autosomal dominant 
polycystic kidney disease (ADPKD), to determine all-cause health care resource 
utilization and all-cause health care expenditures, to determine incremental health care 
resource utilization, and to determine incremental health care expenditures associated 
with ADPKD.  An observational database analysis of a privately insured population was 
conducted using information from a large administrative claims database.  Individuals 18 
years of age or older and enrolled in a tracked health plan anytime during  the period 
from April 1, 2011 through March 31, 2012, were eligible for inclusion in the sample for 
determination of ADPKD prevalence.  To select the sample for estimating all-cause and 
incremental resource utilization and expenditures associated with ADPKD, 
administrative claims and enrollment records from April 1, 2011 through March 31, 2012 
were examined to select individuals 18 years or older with ADPKD (n=3,844) based on 
ICD-9-CM diagnosis codes.  ADPKD patients were linked one-to-one on age and gender 
with individuals without ADPKD resulting in 3,844 persons in the comparison group and 






The number of individuals with ADPKD enrolled anytime during the period from 
April 1, 2011 through March 31, 2012, was identified and divided by the total population 
of covered individuals 18 years or older, during the same one year period to calculate 
prevalence of ADPKD.  All-cause heath care resource utilization among individuals with 
ADPKD  were estimated by counting the total number of hospitalizations, hospital days, 
nursing home confinements, nursing home days, outpatient visits and emergency room 
visits.  All-cause heath care expenditures among individuals with ADPKD were 
estimated by summing standard price amounts from claims related to hospitals, nursing 
homes, outpatient services, emergency rooms, and prescription services.  Incremental 
health care resource utilization and expenditures associated with ADPKD were estimated 
using regression models, adjusting for other risk factors including age, gender, 
comorbidities, cardiovascular disease, diabetes and geographical region.   
The prevalence of autosomal dominant PKD was one in 1,786 persons or 560 
cases per million population.  The 95 percent confidence interval for estimated 
prevalence was 1,742 to 1,833.  Mean annual unadjusted resource utilization of hospital 
days 2.0 versus 0.45, and outpatient visits 21.1 versus 9.7 was substantially higher among 
persons with ADPKD as compared to persons without ADPKD.  Mean annual unadjusted 
total expenditures $23,242 versus $6,230, mean hospital expenditures $6,646 versus 
$1,484, mean outpatient expenditures $12,625 versus $3,225, and mean medication 
expenditures $3,537 versus $1,380, were also higher among ADPKD patients as 
compared to individuals without ADPKD.  Multivariate regression models adjusting for 





ADPKD of  0.68 (0.090) hospital days, equal to 68 additional hospital days per 100 
ADPKD patients, and 6.9 (0.28) outpatient visits, equal to 690 additional visits per 100 
ADPKD patients.  Mean (standard error) incremental total expenditures associated with 
PKD were $7,917 ($431).  Mean incremental expenditures were largest for outpatient 
expenditures at $4,507 ($181), followed by mean incremental hospital expenditures of 
$2,385 ($241), and mean incremental medication expenditures of $1,456 ($71).  Based on 
sub-group analysis by whether diagnosed with end-stage renal disease, mean incremental 
total expenditures were $3,053 ($374) among ADPKD patients without end-stage renal 
disease.   
In conclusion, ADPKD was associated with considerable incremental health care 
resource utilization and expenditures.  Significant illness burden was found even before 







Polycystic Kidney Disease 
Polycystic kidney disease (PKD) is a serious systemic disease that damages the 
kidneys and causes significant morbidity in patients’ lives (Pirson and Chauveau 1999).  
PKD is characterized by development of multiple cysts with gradual kidney enlargement 
and other sequelae including colonic diverticulitis, polycystic liver disease, intracranial 
aneurysms, and cysts in other tissues such as seminal vesicles, arachnoid membranes and 
the pancreas (Alehan, Gurakan, and Agildere 2002; Danaci et al. 1998; Grantham 2008; 
Nicolau et al. 2000; Pirson, Chauveau, and Torres 2002; Schievink et al. 1995; Torres, 
Harris, and Pirson 2007; Wijdicks, Torres, and Schievink 2000).  Kidney cysts are fluid-
filled sacs that result from dilatation of kidney parenchyma (Pirson and Chauveau 1999; 
Wilson 2004).  As cyst develop and grow in size, they replace normal kidney parenchyma 
rendering them dysfunctional (Grantham 2008; Torres, Harris, and Pirson 2007).  PKD 






Forms of PKD 
Non-genetic forms of polycystic kidney diseases are caused by chronic renal 
impairment, medullary sponge kidney disease, drugs and hormones (Pirson and 
Chauveau 1999; Wilson 2004).  Most PKD cases are hereditary, and hereditary cases 
affect approximately 500,000 Americans (Pirson and Chauveau 1999; Wilson 2004; 
Polycystic Kidney Disease Foundation 2000).  Autosomal dominant PKD (ADPKD) is 
the most common genetic form, occurring in 1 in 400 to 1 in 1000 live births and 
accounting for the majority of PKD cases (Grantham 2008; Pirson and Chauveau 1999; 
Torres, Harris, and Pirson 2007).  Autosomal dominant PKD may be asymptomatic for 
several decades but as cysts increase over time, it becomes symptomatic and serious 
sequelae develop.  Autosomal recessive PKD is usually diagnosed during infancy, but it 
is much rarer than autosomal dominant PKD and occurs in only about 1 in 20,000 live 
births (Grantham 2008; Pirson and Chauveau 1999).  Symptom presentation is more 
rapid and occurs at an earlier age for persons with autosomal recessive PKD than for 
persons with autosomal dominant PKD, so that autosomal dominant PKD is more likely 
to be a long term chronic condition (Dell and Avner 2001; Pirson and Chauveau 1999; 







Previous estimates of ADPKD prevalence report occurrence in 1 in 400 to 1 in 
1,000 persons in the United States (Iglesias et al. 1983).  Dalgaard estimated the 
prevalence of ADPKD to be one in 1,000 persons in Copenhagen (Dalgaard 1957). 
Comparatively lower estimates of 1 in 1,111 was reported in France (Simon et al. 1996), 
1 in 2,459 was reported in Wales (Davies et al. 1991), and 1 in 4,033 was reported in 
Japan (Higashihara et al. 1998).  In Seychelles, the estimate of prevalence of ADPKD in 
Caucasian individuals was found to be one in 544 (Yersin et al. 1997).  According to the 
Polycystic Kidney Disease Foundation, ADPKD affects approximately 500,000 
individuals in the United States and that ADPKD affects more individuals as compared to 
cystic fibrosis, muscular dystrophy, hemophilia, Down’s syndrome, sickle cell anemia, 
and Huntington’s disease (Polycystic Kidney Disease Foundation 2000).   
ADPKD often leads to end-stage renal disease, a condition whose prevalence in 
the United States was reported to be 1,752 per million population (United States Renal 
Data System 2012).   In 2010, the prevalence of end-stage renal disease caused by cystic 
kidney disease was 85 per million population (United States Renal Data System 2012).  
Annual incidence rates of end-stage renal disease caused by ADPKD are 8.7 males and 
6.9 females per million in the United States (Stengel et al. 2003), 7.8 males and 6.0 
females per million in Europe (Stengel et al. 2003), and 5.6 males and 4.0 females per 





Pathophysiology of ADPKD 
ADPKD is the most common hereditary kidney disorder (Grantham 2008).  
Genetic mutations in two genes have been identified for ADPKD of which polycystin 1 
(PKD-1) accounts for 85 percent of the cases and polycystin 2 (PKD-2) accounts for 15 
percent of the cases (Grantham 2008; Torres, Harris, and Pirson 2007; Wilson 2004).  It 
is estimated that ADPKD has a 95 percent penetrance that is, 95 percent of those 
individuals detected with mutations in PKD-1 or PKD-2 gene develop the disease 
(Grantham 2008).  The protein products of polycystin-1 and polycystin-2, are found on 
the epithelium of renal tubular cells (Wilson 2004).  Polycystin-1 is a membrane receptor 
that initiates intracellular reactions through phosphorylation whereas polycystin-2 is a 
calcium permeable channel (Torres, Harris, and Pirson 2007; Wilson 2004).  Expression 
of these two proteins in the epithelium of the kidney cells may be altered due to gene 
dose reduction or inactivation (Qian et al. 1996; Torra et al. 1999; Lantinga-van Leeuwen 
et al. 2004).  Polycystin-1 and polycystin-2 form protein complexes and modulate several 
signaling pathways that control cellular functions such as proliferation, apoptosis, cell-
adhesion and differentiation; disturbance in any of these four pathways initiates 
cystogenesis (Nauli et al. 2003; Wilson 2004; Sorenson, Padanilam, and Hammerman 
1996; Trudel, D'Agati, and Costantini 1991; Saadi-Kheddouci et al. 2001; Saburi et al. 
2008; Shannon et al. 2006).   
Magnetic resonance imaging studies by the Consortium of Radiologic Imaging 
Study of PKD found that although cysts expand at the same rate in patients with either 





Grantham and colleagues reported that those with PKD-1 mutations develop renal 
insufficiency approximately 15 years earlier than those with PKD-2 mutations 
(Grantham, Chapman, and Torres 2006).  Comparing phenotypes of ADPKD, Hateboer 
et al. reported that PKD-2 patients experienced fewer complications and lived longer than 
PKD-1 patients (Hateboer et al. 1999).   
Diagnosis of ADPKD 
Diagnosis of ADPKD is made by positive family history and renal imaging 
(Masoumi et al. 2008; Torres, Harris, and Pirson 2007).    For persons with positive 
family history, diagnosis  of ADPKD is confirmed by detecting at least two cysts, in 
either one or both kidneys in persons younger than 30 years of age, at least two cysts in 
each kidney in persons 30 to 59 years of age, or at least four cysts in each kidney in 
persons 60 years of age or older (Ravine et al. 1994).  Detection of liver cysts, pancreatic 
cysts, or both also supports a positive diagnosis of ADPKD (Grantham 2008). Torres et 
al. reported that the absence of family history, a composite of manifestations including 
bilateral kidney enlargement, presence of cysts in both kidneys, liver cysts and absence of 
symptoms indicating a different renal cystic disease, may prompt a prescriptive diagnosis 
for ADPKD (Torres, Harris, and Pirson 2007).   
Pretorius reported that prenatal detection of ADPKD is not evident till the third 
trimester (Pretorius et al. 1987).  However, amongst children, Gabow et al. found that 
cysts were detected by age 5 in approximately 60 percent of children showing presence of 
the PKD-1 gene (Gabow et al. 1997).   The same study also reported that cysts were 





(Gabow et al. 1997).  Fick-Brosnahan and colleagues, in a longitudinal study of disease 
progression in children, set the diagnostic age threshold at 12 years and classified those 
children with less than ten cysts as having mild disease and those having ten or more 
cysts as having severe disease (Fick-Brosnahan et al. 2001).  Nauta reported that the 
probability of detectable cysts rose up to 95 percent by the age of 20 years and that cysts 
were 100 percent detectable by the age of 30 years in individuals carrying the PKD-1 
gene (Nauta 2000).   
Renal ultrasonography is commonly used as a diagnostic technique for detection 
of renal cysts (Elles et al. 1994; Gabow et al. 1997).  Prior to widespread availability of 
ultrasonography, intravenous urography and nephrotomography were used as diagnostic 
techniques, but both methods were only sensitive towards advanced ADPKD (Grossman 
et al. 1983; Rosenfield et al. 1980).  Nicolou et al. found that ultrasonography had good 
sensitivity especially in persons older than 30 years and those with ADPKD caused by 
PKD-1 gene mutations (Nicolau et al. 2000).  However, O’Neill et al. reported that 
ultrasonography was not found to be useful in detecting short-term disease progression 
(O’Neill et al. 2005).   
In a review of literature pertaining to ADPKD diagnosis, Torres et al. summarized 
that genetic testing was a costlier alternative diagnostic procedure compared to 
ultrasonography, and was used as a confirmatory procedure when sonographic scans did 
not provide sufficient proof of presence of renal cysts (Torres, Harris, and Pirson 2007).  
Genetic testing is performed by two methods: linkage or sequence analysis.  Linkage 
analysis uses microsatellite markers for the PKD-1 and PKD-2 genes and compares test 





Harris, and Pirson 2007).  Torres and colleagues reported that linkage analysis was 
constrained by the “availability and willingness of sufficient family members to be 
tested” (Torres, Harris, and Pirson 2007).  Sequence analysis or molecular testing using 
direct DNA analysis has been reported to be effective only up to 65 to 70 percent in 
detecting PKD gene mutations (Rossetti et al. 2002; Rossetti et al. 2001).  Zhao et al. and 
Grantham also  questioned the utility of genetic testing methods due to lower sensitivity 
compared to imaging methods (Grantham 2008; Zhao et al. 2008).     
Disease Progression 
Microscopic studies and analysis of cyst fluid composition have revealed that 
cysts may occur throughout the kidney in any segment of the nephron, including the 
glomeruli, proximal tubules, distal tubules and collecting ducts (Grantham 1993; 
Huseman et al. 1980).  Torres et al. summarize that gene mutation is responsible for 
initiation of cysts alone but cyst enlargement is a process that is perpetuated by other 
intracellular processes (Torres, Harris, and Pirson 2007).  Evidence indicates that gradual 
hyperplasia i.e. slow proliferation of epithelial cells of cysts causes structural changes in 
the wall of the renal tubule (Grantham 1990; Grantham, Chapman, and Torres 2006).  
Detailed morphometric analysis of renal cysts by Grantham revealed that proliferating 
cells in cysts cause an “out-pocketing” of the renal tubule wall, forming a sac-like 
structure (Grantham, Chapman, and Torres 2006; Grantham, Geiser, and Evan 1987).  
The renal tubule is part of the glomerulus or the filtration unit of the kidney, and this unit 





unit  (Grantham, Chapman, and Torres 2006).  The fluid-filled cyst separates from 
healthier tissue, continues proliferation and accumulates more fluid.   
Some study findings indicate that growth of cysts is made possible by remodeling 
and expansion of blood vessels that supply oxygen and nutrients to the cyst cells (Bello-
Reuss, Holubec, and Rajaraman 2001; Reed et al. 2011; Wei et al. 2006).  Other studies 
have detected angiogenic growth factors, that promote formation of new blood vessels, in 
patients with ADPKD (Bello-Reuss, Holubec, and Rajaraman 2001; Fabris et al. 2006; 
Nichols et al. 2004; Wei et al. 2006).  Grantham et al. in a review of literature stated that 
cysts function as autonomous bodies capable of sustaining their growth and consequently 
contribute to enlargement of the kidney (Grantham, Chapman, and Torres 2006). 
Literature reports indicate differing rates of disease progression amongst persons 
with ADPKD (Churchill et al. 1984; Gabow et al. 1992; Hatfield and Pfister 1972; 
Johnson and Gabow 1997; O’Neill et al. 2005; Parfrey et al. 1990).  Churchill and 
colleagues reported that although the probability of developing end-stage renal disease in 
ADPKD patients by age 58 was 0.53, a 95 percent confidence interval of 0.34 to 0.72 
suggested that there was non-uniformity in progression to end-stage renal disease 
(Churchill et al. 1984).  A study by Hatfield and colleagues reported that the frequency of 
finding a polycystic kidney during an autopsy of a person not clinically diagnosed with 
renal disease, was higher than the expected frequency suggested by the clinical 
prevalence of the disease (Hatfield and Pfister 1972).  In a study of 17 families with 
ADPKD, Parfrey et al. found that 50 percent of ADPKD patients at age 58 years were 





Factors Affecting Disease Progression in ADPKD 
Studies reporting non-uniform progression towards end-stage renal disease in 
individuals with ADPKD, have suggested the presence of underlying factors in addition 
to the mutated PKD genes that may contribute to disease progression (Gabow et al. 
1992).  Gabow et al. in their study of 580 subjects with ADPKD, identified that the PKD-
1 gene, younger age at diagnosis, male gender , hypertension, increased left ventricular 
mass, liver cysts in women, three or more pregnancies, gross hematuria i.e. blood in 
urine, urinary tract infection in men and renal volume were markers of disease 
progression and poor renal outcomes (Gabow et al. 1992).  O’Neill et al. documented that 
increasing total renal volume was associated with disease progression (O’Neill et al. 
2005).  Johnson et al. reported that other than having the PKD gene,  factors associated 
with higher risk of disease progression included being diagnosed after the age of 30 
years, presenting hypertension before the age of 35 years, and having an episode of gross 
hematuria (blood in urine) before the age of 30 years (Johnson and Gabow 1997). 
Chapman reported that outcome measures of renal disease progression accepted 
by the Food and Drug Administration include frequency or time to end-stage renal 
disease, doubling of serum creatinine, change in the rate of loss of renal function (serum 
creatinine, reciprocal of serum creatinine, or glomerular filtration rate [GFR]), change in 
proteinuria, protocol biopsy and death (Chapman 2008),  Prior evidence has shown that 
cystic growth and expansion is a gradual process and ADPKD remains asymptomatic for 
several decades before renal dysfunction manifests itself (Chapman 2008; Chapman et al. 





recent studies suggest using total kidney volume as a more reliable marker of disease 
progression and recommend its use as a surrogate marker in clinical trials of potential 
therapies for ADPKD (Chapman 2008; Grantham, Chapman, and Torres 2006).   
Renal Manifestations of ADPKD 
Renal manifestations of ADPKD are associated with both the rate and extent of 
cystic growth and development.  A summary of literature regarding renal manifestations 
of ADPKD and, brief descriptions of structural and functional changes in the kidneys and 
resulting morbidity are presented below. 
Renal Size and Volume 
A longitudinal mapping of 241 patients with ADPKD using magnetic resonance 
imaging, found that total cyst volume and kidney volume increase as the disease 
progresses (Chapman et al. 2003; Grantham, Chapman, and Torres 2006).  The cohort 
demonstrated gradual decrease in kidney function, measured by the glomerular filtration 
rate, with increasing kidney volumes and cyst volumes (Chapman 2008).  Thomsen et al. 
studied 43 adults with PKD and compared their kidney volumes and kidney function to 
497 persons with no evidence of kidney disease.  Compared to persons with no renal 
disease, the mean kidney volume for PKD patients with normal kidney function was 
1,212 (standard deviation ± 411) cm3 whereas the mean kidney volume for PKD patients 
with severely decreased function was almost twice as high 2,053 (standard deviation ± 





glomerular filtration had a negative curvilinear association such that the rate of decline in 
glomerular filtration rate was gradual up to a point where the kidneys became 
substantially enlarged and rapid once a critical size had been reached (Franz and Reubi 
1983).  Fick-Brosnahan et al. in their longitudinal study of 229 patients with PKD also 
reported an inverse relationship between absolute kidney volume and glomerular 
filtration rate and suggested that the rate of renal volume growth may be a clinically 
significant surrogate marker of disease progression in ADPKD (Fick-Brosnahan et al. 
2002). 
Prior studies of ADPKD patients have reported that growing kidney volume and 
resultant abdominal enlargement affect posture, cause chronic lower back pain, early 
satiety, cause breathing trouble and sleep disturbance by impairing motion of the 
diaphragm, and raise concerns about body image (Grantham, Chapman, and Torres 2006; 
Perrone 2010).  Research reports also indicate that enlarged kidneys may increase the risk 
of injury from use of seat-belts that may result in cyst rupture and hematuria (Amend and 
Galen 1973; Grantham, Chapman, and Torres 2006; Perrone 2010). 
Renal Insufficiency and Failure 
Development of urinary concentration defects, glomerular hyperfiltration, 
development of hypertension and reduction in renal blood flow occur with progression of 
ADPKD (Bouby et al. 1990; Bouby, Hassler, and Bankir 1999; Chapman et al. 1990; 
Torres, Keith, et al. 1994; Torres et al. 1991; Watson et al. 1992; Wong et al. 2004; 
Bankir et al. 1993).  In an early longitudinal study of 346 persons with polycystic kidneys 





renal insufficiency (Dalgaard 1957).  Case studies, however, have reported variable 
observations regarding development of renal insufficiency and renal failure in ADPKD 
patients (Franz and Reubi 1983; Higgins 1952; Milutinovic et al. 1984; Rall and Odel 
1949; Simon and Thompson 1955).  Prior research findings indicate that renal 
parenchyma not affected by cysts compensate for the loss of glomerular filtration units to 
cysts (Grantham 2008; Torres and Grantham 2007).  Grantham et al. summarized that 
despite development of cysts from childhood, compensatory mechanisms ensure that 
kidney function of a diseased individual may be indistinguishable from that of a normal 
individual (Grantham 2008).   
Renal function in individuals with ADPKD declines around the fourth or fifth 
decade of life, with an annual rate of decline in glomerular filtration rate ranging from 4.4 
to 5.9 mL/min per year (Torres and Harris 2009).  Mitcheson and colleagues reported that 
approximately 70 percent of patients with ADPKD developed renal insufficiency if they 
survived to age 65 (Mitcheson, Williams, and Castro 1977).   Churchill et al. found that 
the probability of being alive and not having renal failure was 77 percent by age 50, 57 
percent by age 58, and 52 percent by age 73 (Churchill et al. 1984).   
Pain 
Pain is the most often reported symptom among patients with ADPKD and often 
leads to initial diagnosis (Thanos, Farmakis, and Davillas 1989; Demetriou et al. 2000; 
Segal, Spataro, and Barbaric 1977; Milutinovic et al. 1990).  Bajwa et al. found that 
approximately 60 percent of ADPKD patients experienced flank pain with or without 





patients and classified patterns of pain (Bajwa et al. 2004).  The most common type of 
pain was that of the lower back (71.3 percent), followed by abdominal pain (61.4 percent) 
(Bajwa et al. 2004).  Of those reporting abdominal pain, the experience of pain was 
described as dull (49.5 percent), uncomfortable fullness (42.7 percent), stabbing pain 
(40.4percent), and cramping pain (33 percent) (Bajwa et al. 2004).   
In children with ADPKD, pain is a common phenomenon despite the finding that 
hematuria was rarely reported (Bajwa et al. 2001; Bajwa et al. 2004; Fick et al. 1994; 
Fick et al. 1993; Fick-Brosnahan et al. 2001).  On the other hand,  cyst rupture or 
hemorrhage, infection in cysts, passage of kidney stones and pyelonephritis have been 
reported as common causes of pain among adults with ADPKD (Bajwa et al. 2001; 
Bajwa et al. 2004; Fick et al. 1994; Fick et al. 1993; Fick-Brosnahan et al. 2001).  
Hemorrhage from trauma to polycystic kidneys has been reported to occur in 
approximately 60 percent of individuals (Gabow et al. 1992; Gabow, Duley, and Johnson 
1992; Dalgaard 1957).  Presence of pain, hematuria and renal stones have been reported 
to have a positive correlation with extent of kidney enlargement (Gabow et al. 1990; 
Johnson and Gabow 1997).   
Hypertension 
Renal cyst enlargement causes alterations in renal vasculature causing diminished 
supply of oxygen to tissues and stimulating release of renin and activation of the renin-
angiotensin-aldosterone system (Lawson, Doulton, and MacGregor 2006; Chapman et al. 
1990; Doulton et al. 2006; Schrier 2009; Torres et al. 1992; Torres et al. 1991).  The 





and activation of this pathway in persons with ADPKD results in hypertension and cystic 
growth (Chapman et al. 1990).  A positive association between hypertension and renal 
size in ADPKD is a common finding across several studies (Gabow 1993; Gabow et al. 
1990; Gabow, Duley, and Johnson 1992; Gabow et al. 1992; Ong and Harris 2005; 
Chapman 2003; Martinez and Grantham 1995; Chapman et al. 2003; Fick-Brosnahan et 
al. 2002; Kelleher et al. 2004; Nicolau et al. 2000; Thomsen et al. 1981; Chapman and 
Schrier 1991; Schrier, McFann, and Johnson 2003; Seeman et al. 2003; Grantham 1997; 
Seeman et al. 1997).   
Kelleher et al. reported presence of hypertension, blood pressure greater than 
140/90 mm Hg, was present in approximately 50 percent of patients aged 20 to 34 years 
with ADPKD and normal renal function and in 100 percent of patients with end-stage 
renal disease (Kelleher et al. 2004).  In a cross-sectional study of 241 patients with 
ADPKD, higher mean kidney volume was observed in hypertensive patients than in the 
normotensive group (Chapman et al. 2003).  Early diagnosis of hypertension is essential 
to delay development of and control risk of morbidity associated with cardiovascular 
disease (Iglesias et al. 1983; Ecder et al. 2000; Fick et al. 1995).   However, Torres et al. 
report that the diagnosis of hypertension in ADPKD is often delayed (Torres, Harris, and 
Pirson 2007).  Prior reports have shown that hypertension had occurred before the renal 
function decline was detected in persons with ADPKD and that hypertension was 
associated with faster progression to end-stage renal disease and increased mortality from 






Persons with ADPKD develop kidney stones caused by calcification in cysts as 
well as calcification in renal cells un-affected by cysts  (Grampsas et al. 2000; Torres et 
al. 1988; Levine and Grantham 1992; Dimitrakov and Simeonov 1994).  Prior studies 
have found that about 20 to 36 percent of persons with ADPKD had renal stones 
(Dimitrakov and Simeonov 1994; Levine and Grantham 1992; Torres et al. 1988).  Since 
Torres et al. and Dimitrakov et al. found that only 20 to 28 percent of ADPKD patients 
had symptomatic renal stones, it is important to note that symptoms from kidney stones 
remain hidden in a majority of ADPKD patients (Dimitrakov and Simeonov 1994; Torres 
et al. 1988).  Grampsas et al. have reported that higher cyst numbers and larger cysts 
were observed in patients with stones compared to patients without renal stones 
(Grampsas et al. 2000).  Patients with ADPKD-related renal stones have been reported to 
have flank pain, pain from urinary tract obstruction, hematuria and urinary tract infection 
(Masoumi et al. 2008). 
Proteinuria 
In persons with ADPKD, presence of proteinuria or excessive excretion of 
essential proteins in urine, is considered to be indicative of disease progression (Masoumi 
et al. 2008).  Two studies have found that proteinuria is more pronounced in ADPKD 
patients with the PKD-1 mutation than those ADPKD patients with the PKD-2 mutation 
(Chapman et al. 2003; Grantham, Chapman, and Torres 2006).  In a study of 270 patients 





and all patients with proteinuria presented with concomitant hypertension (Chapman et 
al. 1994).  The authors also reported that proteinuria was associated with advanced renal 
functional decline, advanced disease progression, hypertension and hematuria (Chapman 
et al. 1994).   
Extra-Renal Manifestations of ADPKD 
ADPKD may be associated with polycystic liver disease, cysts in seminal 
vesicles, pancreas and arachnoid membrane, intracranial aneurysms  and colonic 
diverticulitis (Danaci et al. 1998; Wijdicks, Torres, and Schievink 2000; Schievink et al. 
1995; Alehan, Gurakan, and Agildere 2002; Nicolau et al. 2000; Grantham 2008; Torres, 
Harris, and Pirson 2007; Pirson, Chauveau, and Torres 2002).  A summary of literature 
on extra-renal manifestations of ADPKD are presented below. 
Polycystic Liver Disease 
Polycystic liver disease is the most common extra-renal manifestation in adults  
with ADPKD (80 percent of patients), however, hepatic cysts are rare in children (Torres, 
Harris, and Pirson 2007).  Bae and associates reported that the prevalence of liver cysts 
was 58 percent in 15 to 24 year olds, 85 percent in 25 to 34 year olds, and 94 percent in 
35 to 46 year olds (Bae et al. 2006).  Studies by Torres et al. and Telenti et al. showed 
that complications related to liver cysts may lead to symptoms including, dyspnoea, early 
satiety, gastroesophageal  and mechanical lower-back pain, cyst hemorrhage, infection, 





Cysts in Other Organs 
Cysts in other organs of persons with ADPKD including the seminal vesicles (40 
percent of men), pancreas (5 percent of ADPKD patients), and arachnoid membrane (8 
percent of ADPKD patients) have been reported (Danaci et al. 1998; Wijdicks, Torres, 
and Schievink 2000; Schievink et al. 1995; Alehan, Gurakan, and Agildere 2002; Nicolau 
et al. 2000).  Although reports of cysts in seminal vesicles have come from case reports 
(Shefi et al. 2009; Vecchi et al. 2003; Kanagarajah, Ayyathurai, and Lynne 2012) and 
cross-sectional studies (Torra et al. 2008) minimal clinical consequences have been found 
(Vecchi et al. 2003).  Although pancreatic cysts have been reported in persons with 
ADPKD, the occurrence are mostly asymptomatic (Naitoh et al. 2005; Sakurai et al. 
2001; Başar et al. 2006).  Case studies by Wijdicks et al. and Abderrahim et al. reported 
sub-arachnoid membrane cysts and associated increased risk of subdural hematomas in 
ADPKD patients (Wijdicks, Torres, and Schievink 2000; Abderrahim et al. 2004).   
Vascular Manifestations 
Vascular manifestations of ADPKD include intracranial aneurysms and 
dolichoectasias, thoracic aortic and cervicocephalic artery dissections, and coronary 
artery aneurysms (Griffin et al. 1997; Torres et al. 2001; Qian et al. 2003).  Intracranial 
aneurysms occur in approximately 6 percent of ADPKD patients with negative family 
history and 16 percent of those ADPKD patients with a positive history (Pirson, 
Chauveau, and Torres 2002).  The incidence of rupture of intracranial aneurysms was 1 in 





rate was five-fold greater than in the general population (Ingall et al. 1989; Phillips et al. 
1980).  Rupture of intracranial aneurysms in ADPKD patients has a 35 percent to 55 
percent risk of mortality (Chauveau et al. 1994; Schievink et al. 1992).   
Cardiac Manifestations 
Mitral valve prolapse is the most common valvular abnormality appearing in up to 
25 percent of PKD patients on echocardiography (Hossack et al. 1988; Lumiaho et al. 
2001).  Among adults with ADPKD, the association between hypertension and increased 
risk of cardiovascular morbidity and mortality has been established (Fick et al. 1995; 
Gabow et al. 1990).  Cadnapaphornchai reported that hypertension in children with 
ADPKD was associated with higher left ventricular mass index (Cadnapaphornchai et al. 
2008, 2009).   Children with borderline hypertension were also found to have increased 
left ventricular mass index as compared with affected children with lower blood pressure 
(Cadnapaphornchai et al. 2008). 
Colonic Diverticular Disease 
Colonic diverticular disease or diverticulosis is characterized by out-pocketing of 
the muscular wall of the colon and clinical manifestations including abdominal 
tenderness, fever and leukocytosis (Scheff et al. 1980).  Scheff et al. in a retrospective 
study of individuals with PKD reported that colonic diverticula presented with 
complications such as sepsis resulting from rupture and death (Scheff et al. 1980).  Scheff 





end-stage renal disease (83 percent) than in those end-stage renal disease without 
ADPKD (32 percent) (Scheff et al. 1980).  Similar trends were reported in two other 
research studies.  McCune et al. found that colonic diverticulosis was present in 50 
percent of ADPKD patients with end-stage renal disease versus 15 percent of patients 
with other causes of end-stage renal disease (McCune et al. 1992) and Lederman et al. 
found colonic diverticulosis in 20 percent of ADPKD patients with end-stage renal 
disease versus 3 percent of end-stage renal disease due to other causes (Lederman et al. 
2000).  Sharp et al. however, found that the occurrence of colonic diverticulosis did not 
differ between ADPKD patients without end-stage renal disease and the general 
population (Sharp et al. 1999).   
Treatment of ADPKD 
Medications commonly used to treat disease symptoms and complications of 
ADPKD include analgesics for pain, angiotensin-converting enzyme  inhibitors to control 
hypertension, and antibiotics for cyst infection and urinary-tract infections associated 
with the disease (Torres, Harris, and Pirson 2007).  To date, however, no clinical trial has 
shown benefit of renin-angiotensin-aldosterone system inhibition with anti-hypertensive 
medications on progression to end-stage renal disease or rate of glomerular filtration rate 
decline.   
As cysts grow and proliferate, invasive surgical procedures including cyst 
drainage, renal denervation and nephropexy may be required to relieve intractable pain 
associated with the cysts (Badani, Hemal, and Menon 2004; Elzinga et al. 1992).  No 





trials have provided evidence that a number of drugs including rapamycin (Walz et al. 
2010), tolvaptan (Torres et al. 2011), bosutinib (National Institutes of Health 2011), 
pravastatin (Belibi and Edelstein 2010) and ocreotide (Ruggenenti et al. 2005) may 
reduce cystogenesis.   
Disease Burden 
Chronic kidney disease, regardless of its underlying cause, has been recognized as 
a source of substantial clinical and economic burden.  Smith et al. reported that among 
enrollees of the Kaiser Permanente Northwest Region health maintenance organization, 
chronic kidney disease patients spent approximately $8,000 more than those without it 
and those with chronic kidney disease and chronic kidney disease-related comorbidities 
spent approximately $26,000 more on healthcare than those without chronic kidney 
disease (Smith et al. 2004).  In an observational study of a general population, 
Baumeister et al. reported that persons with chronic kidney disease had approximately 68 
percent higher drug costs, 60 percent higher inpatient costs, 48 percent higher drug costs 
and a 1.40 higher relative risk of hospitalization compared to persons without chronic 
kidney disease (Baumeister et al. 2010).  Alexander at al. estimated all-cause health care 
utilization in a nationally representative population of persons with chronic kidney 
disease in the period from 1988 to 1994 and reported that individuals with late-stage 
chronic kidney disease reported higher mean number of hospitalizations (0.42 ± 0.03) 
than those without chronic kidney disease (0.15 ± 0.01) and mean number of annual 
physician visits (6.53 ± 0.38) compared to those without chronic kidney disease (3.51 ± 





Persons with chronic kidney disease incur substantial costs prior to end-stage 
renal disease and these expenses increase with deteriorating kidney function and onset of 
dialysis (Smith et al. 2004; London et al. 2002; Robbins et al. 2003).  Robbins et al. 
reported that per-patient-per-month charges increased from $4,265 in the pre-dialysis 
period to $15,399 in the two to three months after dialysis initiation (Robbins et al. 2003).   
PKD has been identified as the leading hereditary cause of end-stage renal disease 
in the United States and accounts for approximately five percent of all end-stage renal 
disease cases (United States Renal Data System 2011).  Renal failure occurs by age 60 in 
approximately 50 percent of patients with ADPKD, requiring dialysis or kidney 
transplant (Grantham 2008).  Lentine and colleagues estimated all-cause health care costs 
for persons with ADPKD, stratified those costs by kidney function and reported that 
advancing renal insufficiency was associated with higher health care expenditures 
(Lentine et al. 2010).  However, Lentine et al. did not estimate incremental health care 
resource utilization or expenditures associated with ADPKD (Lentine et al. 2010).  
Medical Resource Utilization and Expenditures 
Studies that estimate expenditures and medical resource utilization associated 
with a disease, provide valuable insight regarding economic burden of the disease and 
indicate the potential savings that may be achieved if the disease were avoided, controlled 
or eliminated (Akobundu et al. 2006; Ament and Evers 1993; Lipscomb, Barnett, et al. 
2009; Lipscomb, Yabroff, et al. 2009; Mushkin and Collings 1959; Rice, Hodgson, and 
Kopstein 1985; Rice 1994, 2000; Tarricone 2006; Wiseman and Mooney 1998).  Data on 





resources towards prevention or treatment of a disease and assessment of financial strain 
a disease has on society, the health care system, stakeholders such as payers, businesses, 
and the government and on patients and their families (Segel 2006; Finkelstein, 
Fiebelkorn, and Wang 2003; Taylor and Sloan 2000; Miller et al. 1998; Thompson et al. 
1998; Goetzel et al. 2004; Hodgson and Meiners 1982).  Monetary values of health care 
events are calculated as either all-cause estimates or incremental estimates.  A brief 
description of methods of cost estimation is presented below. 
All-Cause or Sum of all Costs Approach 
The all-cause approach estimates total expenditure or utilization of persons 
diagnosed with the disease.  When estimating all-cause utilization or expenditures among 
persons diagnosed with the disease, all patients with a diagnosis of the disease are 
identified and all health care utilization as well as health care expenditures are added up, 
regardless of whether these costs directly relate to the disease of interest (Akobundu et al. 
2006).  This method is advantageous for its simplicity but has been reported to 
overestimate  the cost of diseases which are associated with many comorbidities 
(Cummings et al. 2002).  Akobundu et al. state that the all-cause method is better suited 
for making cross-country comparisons regarding burden of illness estimates rather than 






The incremental approach estimates the burden directly associated with the 
disease in particular.  There are two methods of calculating incremental estimates: the 
matching method and the regression method.  In the matching method persons with the 
disease are identified and matched with a cohort of persons without the disease.  Persons 
with the disease are matched with those without the disease on specific demographic 
characteristics including age, gender and race (Balu and Thomas 2006; Birnbaum et al. 
2004; Gabriel et al. 2002).  Incremental burden of the disease is calculated by subtracting 
health care resource utilization or expenditures of persons without the disease from 
corresponding resource utilization or expenditures of persons with the disease.  The 
matching method is based on the premise that the matching process accounts for all 
differences between the cohort with the disease and the one without, such that the only 
remaining difference between them is the presence of the disease (Akobundu et al. 2006).  
Akobundu et al. highlight that the matched control method is a simple technique of 
estimating costs of illness but identification of all relevant comorbid conditions as well as 
potential demographic variables is essential for obtaining accurate estimates (Akobundu 
et al. 2006).   
The regression method has been used by researchers to estimates excess medical 
cost of treating a particular disease (Balu and Thomas 2006; Birnbaum et al. 2004; 
Gabriel et al. 2002; Lozano et al. 1997; Martin et al. 2000).  In this method, a regression 
equation a adjusting for comorbidities and other relevant variables is used to estimate 





1997; Martin et al. 2000).  Total costs for patients with the disease are compared to total 
costs among patients without the disease, and the difference is the estimated regression 
parameter from an equation such as: 
 
Cost = β0 + β1 Disease + β2 Demographic1 + β3 Demographic2 
        + β4 Comorbidity1 + β5 Comorbidity2 + ε 
 
where, “Disease” is a binary variable with a value of ‘1’ for persons with the disease and 
‘0’ for persons without the disease, ‘Demographic1’ and ‘Demographc2’ representing 
relevant demographic characteristics that must be adjusted for, ‘Comorbidity1’ and 
‘Comorbidity2’ representing two comorbid conditions and ‘ε’ is the error term.  The 
incremental cost of the disease is given by the estimate of the parameter β1.  Controlling 
for comorbidities has been highlighted as a critical step of the regression method, and 
insufficient rigor can introduce misspecification bias into the regression parameter 
estimate (Akobundu et al. 2006; Lee, Meyer, and Clouse 2001).  Lee et al. conclude that 
failing to adjust for sufficient comorbid conditions for may result in overestimation of 
costs or adjusting for all comorbidities may underestimate costs of illness (Lee, Meyer, 
and Clouse 2001).  Akobundu et al. conclude that the regression method is the preferred 
method of cost estimation for diseases which are not associated with unobservable factors 






The United States Renal Data System reports annual estimates of prevalence of 
chronic kidney disease; however, this estimate does not provide a breakdown by cause of 
chronic kidney diseases.  This study will provide a current description of epidemiology of 
ADPKD by estimating one year disease prevalence.  There is limited evidence describing 
economic burden of ADPKD.  Although one study estimated health care costs in ADPKD 
stratified by kidney function (Lentine et al. 2010), we found no study that assessed all-
cause health care resource utilization or incremental impact of ADPKD on health care 
resource utilization and health care expenditures.  Understanding incremental health care 
resource utilization and incremental expenditures associated with ADPKD would more 
likely give precise estimate of burden associated with the disease since the regression 
method will identify burden specific to ADPKD.  The findings should provide valuable 
data on the societal impact of the disease. 
Objectives 
This study sought to determine the prevalence of ADPKD in a private pay 
population and to identify demographic and clinical characteristics of patients with PKD.  
Health care resource utilization and health care expenditures in persons with PKD was 
also assessed.  The specific study objectives were to: 
1. determine prevalence of ADPKD  in a private-pay population, 
2. determine all-cause health care resource utilization and expenditures among 





3. determine incremental health care resource utilization associated with ADPKD by 
categories including hospitalizations, hospital days, nursing home visits, nursing 
home length of stay, emergency room encounters and  outpatient encounters, and 
4. determine incremental health care expenditures associated with ADPKD by 
categories including total expenditures, hospital stay, nursing home stay, 






Abderrahim, Ezzedine, Hafedh Hedri, Jannette Laabidi, Lamia Raies, Adel Kheder, Taieb 
Ben Abdallah, Fatma Ben Moussa, and Hedi Ben Maiz. Chronic Subdural 
Haematoma and Autosomal Polycystic Kidney Disease: Report of Two New Cases. 
2004. Nephrology (Carlton) 9 (5): 331-3. 
 
Akobundu, E.bere, Jing Ju, Lisa Blatt, and C. Daniel Mullins. Cost-of-Illness Studies : A 
Review of Current Methods. 2006. Pharmacoeconomics 24 (9): 869-90. 
 
Alehan, Fusun Korkmaz, Berkan Gurakan, and Muhtesem Agildere. Familial Arachnoid 
Cysts in Association with Autosomal Dominant Polycystic Kidney Disease. 2002. 
Pediatrics 110 (1): e13. 
 
Alexander, Marcus, Brian D. Bradbury, Reshma Kewalramani, Arie Barlev, Sarita A. 
Mohanty, and Denise. Globe. Chronic Kidney Disease and Us Healthcare Resource 
Utilization in a Nationally Representative Sample. 2009. Am J Nephrol 29 (5): 473-
482. 
 
Amend, William J., and Malcolm Galen. Polycystic Kidney Disease and Seatbelts. 1973. 
Ann Intern Med 79 (2): 287. 
 
Ament, Andre, and Silvia Evers. Cost of Illness Studies in Health Care: A Comparison of 
Two Cases. 1993. Health Policy 26 (1): 29-42. 
 
Badani, Ketan, Ashok K. Hemal, and Mani Menon. Autosomal Dominant Polycystic 
Kidney Disease and Pain - a Review of the Disease from Aetiology, Evaluation, Past 






Bae, Kyongtae T., Fang Zhu, Arlene B. Chapman, Vicente E. Torres, Jared J. Grantham, 
Lisa M. Guay-Woodford, Deborah A. Baumgarten, Bernard F. King, Louis H. 
Wetzel, Philip J. Kenney, Marijn E. Brummer, William M. Bennett, Saulo Klahr, 
Catherine M. Meyers, Xiaoling Zhang, Paul A. Thompson, J. Philip Miller, and 
Disease and the Consortium for Radiologic Imaging Studies of Polycystic Kidney. 
Magnetic Resonance Imaging Evaluation of Hepatic Cysts in Early Autosomal-
Dominant Polycystic Kidney Disease: The Consortium for Radiologic Imaging 
Studies of Polycystic Kidney Disease Cohort. 2006. Clin J Am Soc Nephrol 1 (1): 
64-69. 
 
Bajwa, Zahid H., Sanjay Gupta, Carol A. Warfield, and Theodore I. Steinman. Pain 
Management in Polycystic Kidney Disease. 2001. Kidney Int 60 (5): 1631-1644. 
 
Bajwa, Zahid H., Khuram A. Sial, Atif B. Malik, and Theodore I. Steinman. Pain Patterns 
in Patients with Polycystic Kidney Disease. 2004. Kidney Int 66 (4): 1561-1569. 
 
Balu, Sanjeev., and Joseph. Thomas, 3rd. Incremental Expenditure of Treating 
Hypertension in the United States. 2006. Am J Hypertens 19 (8): 810-6; discussion 
817. 
 
Bankir, Lise, Mina Ahloulay, Nadine Bouby, Marie-Marcelle Trinh-Trang-Tan, Frédéric 
Machet, Bernard Lacour, and Paul Jungers. Is the Process of Urinary Urea 
Concentration Responsible for a High Glomerular Filtration Rate? 1993. J Am Soc 
Nephrol 4 (5): 1091-1103. 
 
Başar, Ömer, Mehmet Ibiş, Engin Uçar, Ibrahim Ertuğrul, Ö F Yolcu, Seyfettin Köklü, 
Erkan Parlak, and Aysel Ülker. Recurrent Pancreatitis in a Patient with Autosomal-






Baumeister, Sebastian E., Carsten A. Böger, Bernhard K. Krämer, Angela Döring, Dirk 
Eheberg, Beate Fischer, Jurgen John, Wolfgang Koenig, and Christa Meisinger. 
Effect of Chronic Kidney Disease and Comorbid Conditions on Health Care Costs: A 
10-Year Observational Study in a General Population. 2010. Am J Nephrol 31 (3): 
222-229. 
 
Belibi, Franck A, and Charles L Edelstein. Novel Targets for the Treatment of Autosomal 
Dominant Polycystic Kidney Disease. 2010. Expert Opin Investig Drugs 19 (3): 315-
328. 
 
Bello-Reuss, Elsa, Keith Holubec, and Srinivasan Rajaraman. Angiogenesis in 
Autosomal-Dominant Polycystic Kidney Disease. 2001. Kidney Int 60 (1): 37-45. 
 
Birnbaum, Howard G., Stephanie A. Leong, Emily F. Oster, Kraig Kinchen, and Peter 
Sun. Cost of Stress Urinary Incontinence: A Claims Data Analysis. 2004. 
Pharmacoeconomics 22 (2): 95-105. 
 
Bouby, Nadine, Sebastian Bachmann, Daniel Bichet, and Lise Bankir. Effect of Water 
Intake on the Progression of Chronic Renal Failure in the 5/6 Nephrectomized Rat. 
1990. Am J Physiol Renal Physiol 258 (4): F973-F979. 
 
Bouby, Nadine, Christine Hassler, and Lise Bankir. Contribution of Vasopressin to 
Progression of Chronic Renal Failure: Study in Brattleboro Rats. 1999. Life Sci 65 
(10): 991-1004. 
 
Cadnapaphornchai, Melissa A., Kim McFann, John D. Strain, Amirali Masoumi, and 
Robert W. Schrier. Increased Left Ventricular Mass in Children with Autosomal 
Dominant Polycystic Kidney Disease and Borderline Hypertension. 2008. Kidney Int 






Cadnapaphornchai, Melissa A., Kim McFann, John D. Strain, Amirali Masoumi, and 
Robert W. Schrier. Prospective Change in Renal Volume and Function in Children 
with Adpkd. 2009. Clin J Am Soc Nephrol 4 (4): 820-829. 
 
Chapman, Arlene B. Cystic Disease in Women: Clinical Characteristics and Medical 
Management. 2003. Adv Ren Replace Ther 10 (1): 24-30. 
 
Chapman, Arlene B. Approaches to Testing New Treatments in Autosomal Dominant 
Polycystic Kidney Disease: Insights from the Crisp and Halt-Pkd Studies. 2008. Clin 
J Am Soc Nephrol 3 (4): 1197-1204. 
 
Chapman, Arlene B., Lisa M. Guay-Woodford, Jared J. Grantham, Vicente E. Torres, 
Kyongtae T. Bae, Deborah A. Baumgarten, Philip J. Kenney, Bernard F. King, Jr., 
James F. Glockner, Louis H. Wetzel, Marijn E. Brummer, W. Charles O'Neill, 
Michelle L. Robbin, William M. Bennett, Saulo Klahr, Gladys H. Hirschman, Paul 
L. Kimmel, Paul A. Thompson, and J. Philip Miller. Renal Structure in Early 
Autosomal-Dominant Polycystic Kidney Disease (Adpkd): The Consortium for 
Radiologic Imaging Studies of Polycystic Kidney Disease (Crisp) Cohort1. 2003. 
Kidney Int 64 (3): 1035-1045. 
 
Chapman, Arlene B., Ann   Johnson, Patricia A. Gabow, and Robert W. Schrier. The 
Renin-Angiotensin-Aldosterone System and Autosomal Dominant Polycystic Kidney 
Disease. 1990. N Engl J Med 323 (16): 1091-6. 
 
Chapman, Arlene B., Ann M. Johnson, Patricia A. Gabow, and Robert W. Schrier. Overt 
Proteinuria and Microalbuminuria in Autosomal Dominant Polycystic Kidney 
Disease. 1994. J Am Soc Nephrol 5 (6): 1349-1354. 
 
Chapman, Arlene B., and Robert W. Schrier. Pathogenesis of Hypertension in Autosomal 





Chauveau, Dominique, Yves Pirson, C Verellen-Dumoulin, Anne Macnicol, Ana 
Gonzalo, and Jean-Pierre Grünfeld. Intracranial Aneurysms in Autosomal Dominant 
Polycystic Kidney Disease. 1994. Kidney Int 45 (4): 1140-1146. 
 
Churchill, David N., John C. Bear, Janet Morgan, Ronald H. Payne, Patrick J. 
McManamon, and M. Henry Gault. Prognosis of Adult Onset Polycystic Kidney 
Disease Re-Evaluated. 1984. Kidney Int 26 (2): 190-3. 
 
Cummings, Jeffery L., Janet C. Frank, Debra Cherry, Neal D. Kohatsu, Bryan Kemp, 
Linda Hewett, and Brian Mittman. Guidelines for Managing Alzheimer's Disease: 
Part I. Assessment. 2002. Am Fam Physician 65 (11): 2263-72. 
 
Dalgaard, Ole. Z. Bilateral Polycystic Disease of the Kidneys; a Follow-up of Two 
Hundred and Eighty-Four Patients and Their Families. 1957. Acta Med Scand Suppl 
328 1-255. 
 
Danaci, Murat, Tekin Akpolat, Murat Bastemir, Saban Sarikaya, Huseyin Akan, Mustafa 
B. Selcuk, and Kuddusi Cengiz. The Prevalence of Seminal Vesicle Cysts in 
Autosomal Dominant Polycystic Kidney Disease. 1998. Nephrol Dial Transplant 13 
(11): 2825-2828. 
 
Davies, Felicity, Gerald A. Coles, Peter S. Harper, Andrew J. Williams, Christine Evans, 
and Dennis Cochlin. Polycystic Kidney Disease Re-Evaluated: A Population-Based 
Study. 1991. Q J Med 79 (290): 477-85. 
 
Dell, Katherine M.R., and Ellis D. Avner. Polycystic Kidney Disease, Autosomal 
Recessive. 2001. GeneReviews™ [Internet].  Pagon RA, Adam MP, Bird TD, et al. 






Demetriou, Kyproulla, Chrysa Tziakouri, Kristiana Anninou, Andri Eleftheriou, Michalis 
Koptides, Alexia Nicolaou, C Constantinou Deltas, and Alkis Pierides. Autosomal 
Dominant Polycystic Kidney Disease-Type 2. Ultrasound, Genetic and Clinical 
Correlations. 2000. Nephrol Dial Transplant 15 (2): 205-11. 
 
Dimitrakov, D., and S. Simeonov. Studies on Nephrolithiasis in Patients with Autosomal 
Dominant Polycystic Kidney Disease. 1994. Folia Med (Plovdiv) 36 (3): 27-30. 
 
Doulton, Timothy W., Anand K. Saggar-Malik, Feng J. He, Christine Carney, Nirmala D. 
Markandu, Guiseppe. A. Sagnella, and Graham A. MacGregor. The Effect of Sodium 
and Angiotensin-Converting Enzyme Inhibition on the Classic Circulating Renin-
Angiotensin System in Autosomal-Dominant Polycystic Kidney Disease Patients. 
2006. J Hypertens 24 (5): 939-45. 
 
Ecder, Tevfik, Arlene B Chapman, Godela M Brosnahan, Charles L Edelstein, Ann M 
Johnson, and Robert W Schrier. Effect of Antihypertensive Therapy on Renal 
Function and Urinary Albumin Excretion in Hypertensive Patients with Autosomal 
Dominant Polycystic Kidney Disease. 2000. Am J Kidney Dis 35 (3): 427-32. 
 
Elles, Rob G., Kathy A. Hodgkinson, Netar P. Mallick, Donal J. O'Donoghue, Andrew P. 
Read, Stephen Rimmer, E. Ann Watters, and Rodney Harris. Diagnosis of Adult 
Polycystic Kidney Disease by Genetic Markers and Ultrasonographic Imaging in a 
Voluntary Family Register. 1994. J Med Genet 31 (2): 115-20. 
 
Elzinga, Lawrence W., John M. Barry, Vincente E. Torres, Horst Zincke, Heinz W. 
Wahner, Suzanne Swan, and William M. Bennett. Cyst Decompression Surgery for 







Fabris, Luca, Massimiliano Cadamuro, Romina Fiorotto, Tania Roskams, Carlo Spirlì, 
Saida Melero, Aurelio Sonzogni, Ruth E Joplin, Lajos Okolicsanyi, and Mario 
Strazzabosco. Effects of Angiogenic Factor Overexpression by Human and Rodent 
Cholangiocytes in Polycystic Liver Diseases. 2006. Hepatology 43 (5): 1001-12. 
 
Fick-Brosnahan, Godela M., Mark M. Belz, Kim K. McFann, Ann M. Johnson, and 
Robert W. Schrier. Relationship between Renal Volume Growth and Renal Function 
in Autosomal Dominant Polycystic Kidney Disease: A Longitudinal Study. 2002. 
Am J Kidney Dis 39 (6): 1127-1134. 
 
Fick-Brosnahan, Godela M., Zung Vu Tran, Ann M. Johnson, John D. Strain, and Patricia 
A. Gabow. Progression of Autosomal-Dominant Polycystic Kidney Disease in 
Children1. 2001. Kidney Int 59 (5): 1654-1662. 
 
Fick, Godela M, Irene T Duley, Ann M Johnson, John D Strain, Michael L Manco-
Johnson, and Patricia A Gabow. The Spectrum of Autosomal Dominant Polycystic 
Kidney Disease in Children. 1994. J Am Soc Nephrol 4 (9): 1654-1660. 
 
Fick, Godela M, Ann M Johnson, William S Hammond, and Patricia A Gabow. Causes of 
Death in Autosomal Dominant Polycystic Kidney Disease. 1995. J Am Soc Nephrol 
5 (12): 2048-56. 
 
Fick, Godela M, Ann M Johnson, John D Strain, William J Kimberling, Shrawan Kumar, 
Michael L Manco-Johnson, Irene T Duley, and Patricia A Gabow. Characteristics of 
Very Early Onset Autosomal Dominant Polycystic Kidney Disease. 1993. J Am Soc 
Nephrol 3 (12): 1863-1870. 
 
Finkelstein, Eric A., Ian C. Fiebelkorn, and Guijing Wang. National Medical Spending 
Attributable to Overweight and Obesity: How Much, and Who's Paying? 2003. 





Franz, Kathrin A., and François C. Reubi. Rate of Functional Deterioration in Polycystic 
Kidney Disease. 1983. Kidney Int 23 (3): 526-9. 
 
Gabow, Patricia  A., Irene. Duley, and Ann M. Johnson. Clinical Profiles of Gross 
Hematuria in Autosomal Dominant Polycystic Kidney Disease. 1992. Am J Kidney 
Dis 20 (2): 140-3. 
 
Gabow, Patricia A, William J Kimberling, John D Strain, Michael L Manco-Johnson, and 
Ann M Johnson. Utility of Ultrasonography in the Diagnosis of Autosomal 
Dominant Polycystic Kidney Disease in Children. 1997. J Am Soc Nephrol 8 (1): 
105-110. 
 
Gabow, Patricia A., Arlene B. Chapman, Ann M. Johnson, Douglas J. Tangel, Irene T. 
Duley, William D. Kaehny, Michael Manco-Johnson, and Robert W. Schrier. Renal 
Structure and Hypertension in Autosomal Dominant Polycystic Kidney Disease. 
1990. Kidney Int 38 (6): 1177-1180. 
 
Gabow, Patricia A., Ann M. Johnson, William D. Kaehny, William J. Kimberling, Dennis 
C. Lezotte, Irene T. Duley, and Richard H. Jones. Factors Affecting the Progression 
of Renal Disease in Autosomal-Dominant Polycystic Kidney Disease. 1992. Kidney 
Int 41 (5): 1311-1319. 
 
Gabow, Patricia. A. Autosomal Dominant Polycystic Kidney Disease. 1993. N Engl J 
Med 329 (5): 332-42. 
 
Gabriel, Sherine E., Anna N. Tosteson, Cynthia L. Leibson, Cynthia S. Crowson, 
Gregory R. Pond, Carol S. Hammond, and L. Joseph Melton, 3rd. Direct Medical 






Goetzel, Ron Z., Stacey R. Long, Ronald J. Ozminkowski, Kevin Hawkins, Shaohung 
Wang, and Wendy Lynch. Health, Absence, Disability, and Presenteeism Cost 
Estimates of Certain Physical and Mental Health Conditions Affecting U.S. 
Employers. 2004. J Occup Environ Med 46 (4): 398-412. 
 
Grampsas, Samuel A., Paramjit S. Chandhoke, Jie Fan, Michael A. Glass, Ronald 
Townsend, Ann M. Johnson, and Patricia Gabow. Anatomic and Metabolic Risk 
Factors for Nephrolithiasis in Patients with Autosomal Dominant Polycystic Kidney 
Disease. 2000. Am J Kidney Dis 36 (1): 53-57. 
 
Grantham, Jared J. Polycystic Kidney Disease: Neoplasia in Disguise. 1990. Am J 
Kidney Dis 15 (2): 110-6. 
 
Grantham, Jared J. 1992 Homer Smith Award. Fluid Secretion, Cellular Proliferation, and 
the Pathogenesis of Renal Epithelial Cysts. 1993. J Am Soc Nephrol 3 (12): 1841-57. 
 
Grantham, Jared J. Mechanisms of Progression in Autosomal Dominant Polycystic 
Kidney Disease. 1997. Kidney Int Suppl 63 S93-7. 
 
Grantham, Jared J. Autosomal Dominant Polycystic Kidney Disease. 2008. N Engl J Med 
359 (14): 1477-1485. 
 
Grantham, Jared J., Arlene B. Chapman, and Vicente E. Torres. Volume Progression in 
Autosomal Dominant Polycystic Kidney Disease: The Major Factor Determining 
Clinical Outcomes. 2006. Clin J Am Soc Nephrol 1 (1): 148-157. 
 
Grantham, Jared J., James L. Geiser, and Andrew P. Evan. Cyst Formation and Growth in 






Griffin, Matthew. D., Vicente. E. Torres, Joseph. P. Grande, and Rajiv. Kumar. Vascular 
Expression of Polycystin. 1997. J Am Soc Nephrol 8 (4): 616-626. 
 
Grossman, Herman, Eric R. Rosenberg, James D. Bowie, Panol Ram, and David F. 
Merten. Sonographic Diagnosis of Renal Cystic Diseases. 1983. AJR Am J 
Roentgenol 140 (1): 81-5. 
 
Harris, Peter C., Kyongtae T. Bae, Sandro Rossetti, Vicente E. Torres, Jared J. Grantham, 
Arlene B. Chapman, Lisa M. Guay-Woodford, Bernard F. King, Louis H. Wetzel, 
Deborah A. Baumgarten, Philip J. Kenney, Mark Consugar, Saulo Klahr, William M. 
Bennett, Catherine M. Meyers, Qin Zhang, Paul A. Thompson, Fang Zhu, and J. 
Philip Miller. Cyst Number but Not the Rate of Cystic Growth Is Associated with the 
Mutated Gene in Autosomal Dominant Polycystic Kidney Disease. 2006. J Am Soc 
Nephrol 17 (11): 3013-3019. 
 
Hateboer, Nick, Marjan A. v Dijk, Nadja Bogdanova, Eliecer Coto, Anand K. Saggar-
Malik, Jose L. San Millan, Roser Torra, Martijn Breuning, and David Ravine. 
Comparison of Phenotypes of Polycystic Kidney Disease Types 1 and 2. 1999. The 
Lancet 353 (9147): 103-107. 
 
Hatfield, Philip M, and Richard C Pfister. Adult Polycystic Disease of the Kidneys 
(Potter Type 3). 1972. JAMA: Journal of the American Medical Association 222 
(12): 1527-1531. 
 
Higashihara, Eiji, Kikuo Nutahara, Masayo Kojima, Akiko Tamakoshi, Ohno Yoshiyuki, 
Hideto Sakai, and Kiyoshi Kurokawa. Prevalence and Renal Prognosis of Diagnosed 







Higgins, Charles. C. Bilateral Polycystic Kidney Disease; Review of Ninety-Four Cases. 
1952. AMA Arch Surg 65 (2): 318-29. 
 
Hodgson, Thomas A., and Mark R. Meiners. Cost-of-Illness Methodology: A Guide to 
Current Practices and Procedures. 1982. Milbank Mem Fund Q Health Soc 60 (3): 
429-62. 
 
Hossack, Kenneth F, Cheryl L Leddy, Ann M Johnson, Robert W Schrier, and Patricia A 
Gabow. Echocardiographic Findings in Autosomal Dominant Polycystic Kidney 
Disease. 1988. N Engl J Med 319 (14): 907-12. 
 
Huseman, Richard, Ann Grady, Daniel Welling, and Jared J Grantham. Macropuncture 
Study of Polycystic Disease in Adult Human Kidneys. 1980. Kidney Int 18 (3): 375-
85. 
 
Iglesias, Carmen G., Vincente E. Torres, Kenneth P. Offord, Keith E. Holley, C. Mary 
Beard, and Leonard T. Kurland. Epidemiology of Adult Polycystic Kidney Disease, 
Olmsted County, Minnesota: 1935-1980. 1983. Am J Kidney Dis 2 (6): 630-9. 
 
Ingall, Timothy J, Jack P Whisnant, David O Wiebers, and WM O'Fallon. Has There 
Been a Decline in Subarachnoid Hemorrhage Mortality? 1989. Stroke 20 (6): 718-
724. 
 
Johnson, Ann. M., and Patricia. A. Gabow. Identification of Patients with Autosomal 
Dominant Polycystic Kidney Disease at Highest Risk for End-Stage Renal Disease. 
1997. J Am Soc Nephrol 8 (10): 1560-1567. 
 
Kanagarajah, Prasanth, Raj Ayyathurai, and Ccharles M. Lynne. Male Infertility and 
Adult Polycystic Kidney Disease–Revisited: Case Report and Current Literature 





Kelleher, Catherine L., Kim K. McFann, Ann M. Johnson, and Robert W. Schrier. 
Characteristics of Hypertension in Young Adults with Autosomal Dominant 
Polycystic Kidney Disease Compared with the General U.S. Population[Ast]. 2004. 
Am J Hypertens 17 (11): 1029-1034. 
 
Lantinga-van Leeuwen, Irma S, Johannes G Dauwerse, Hans J Baelde, Wouter N 
Leonhard, Annemieke van de Wal, Christopher J Ward, Sjef Verbeek, Marco C 
DeRuiter, Martijn H Breuning, and Emile de Heer. Lowering of Pkd1 Expression Is 
Sufficient to Cause Polycystic Kidney Disease. 2004. Hum Mol Genet 13 (24): 3069-
77. 
 
Lawson, Catherine R., Timothy W. Doulton, and Graham A. MacGregor. Autosomal 
Dominant Polycystic Kidney Disease: Role of the Renin-Angiotensin System in 
Raised Blood Pressure in Progression of Renal and Cardiovascular Disease. 2006. J 
Renin Angiotensin Aldosterone Syst 7 (3): 139-45. 
 
Lederman, Eric D, Guy McCoy, David J Conti, and Edward C. Lee. Diverticulitis and 
Polycystic Kidney Disease. 2000. Am Surg 66 (2): 200-3. 
 
Lee, David W., Jay W. Meyer, and Jon Clouse. Implications of Controlling for Comorbid 
Conditions in Cost-of-Illness Estimates: A Case Study of Osteoarthritis from a 
Managed Care System Perspective. 2001. Value Health 4 (4): 329-34. 
 
Lentine, Krista L., Huiling Xiao, Gerardo Machnicki, Adrian Gheorghian, and Mark A. 
Schnitzler. Renal Function and Healthcare Costs in Patients with Polycystic Kidney 
Disease. 2010. Clin J Am Soc Nephrol 5 (8): 1471-1479. 
 
Levine, Errol, and Jared J. Grantham. Calcified Renal Stones and Cyst Calcifications in 
Autosomal Dominant Polycystic Kidney Disease: Clinical and Ct Study in 84 





Lipscomb, Joseph, Paul G. Barnett, Martin L. Brown, William Lawrence, and K. Robin 
Yabroff. Advancing the Science of Health Care Costing. 2009. Med Care 47 (7 
Suppl 1): S120-6. 
 
Lipscomb, Joseph, K. Robin Yabroff, Martin L. Brown, William Lawrence, and Paul G. 
Barnett. Health Care Costing: Data, Methods, Current Applications. 2009. Med Care 
47 (7 Suppl 1): S1-6. 
 
London, Roger, Amy Solis, George A. Goldberg, Sally Wade, and Seonyoung Ryu. 
Health Care Resource Utilization and the Impact of Anemia Management in Patients 
with Chronic Kidney Disease. 2002. Am J Kidney Dis 40 (3): 539-48. 
 
Lozano, Paula, Paul Fishman, Michael VonKorff, and Julia Hecht. Health Care 
Utilization and Cost among Children with Asthma Who Were Enrolled in a Health 
Maintenance Organization. 1997. Pediatrics 99 (6): 757-64. 
 
Lumiaho, Anne, Risto Ikäheimo, Raija Miettinen, Lea Niemitukia, Tomi Laitinen, Arto 
Rantala, Erkki Lampainen, Markku Laakso, and Juha Hartikainen. Mitral Valve 
Prolapse and Mitral Regurgitation Are Common in Patients with Polycystic Kidney 
Disease Type 1. 2001. Am J Kidney Dis 38 (6): 1208-1216. 
 
Martin, Bradley C., Jean F. Ricci, Jeffrey A. Kotzan, Kathleen Lang, and Joseph Menzin. 
The Net Cost of Alzheimer Disease and Related Dementia: A Population-Based 
Study of Georgia Medicaid Recipients. 2000. Alzheimer Dis Assoc Disord 14 (3): 
151-9. 
 
Martinez, John R , and Jared J  Grantham. Polycystic Kidney Disease: Etiology, 






Masoumi, Amirali , Berenice  Reed-Gitomer, Catherine  Kelleher, Mir Reza  Bekheirnia, 
and Robert W.  Schrier. Developments in the Management of Autosomal Dominant 
Polycystic Kidney Disease. 2008. Ther Clin Risk Manag 4 (2): 393–407. 
 
McCune, Thomas R, William A Nylander, David H Van Buren, Robert E Richie, Robert 
C Jr MacDonell, H Keith  Johnson, Jr Shull Harrison, Clifford K Cate, and J Harold. 
Helderman. Colonic Screening Prior to Renal Transplantation and Its Impact on 
Post-Transplant Colonic Complications. 1992. Clin Transplant 6 (2): 91-6. 
 
Miller, Leonard S., Xiulan Zhang, Dorothy P. Rice, and Wendy Max. State Estimates of 
Total Medical Expenditures Attributable to Cigarette Smoking, 1993. 1998. Public 
Health Rep 113 (5): 447-58. 
 
Milutinovic, Jovan, Philip J. Fialkow, Lawrence Y. Agodoa, Leon A. Phillips, Thomas G. 
Rudd, and Jean I. Bryant. Autosomal Dominant Polycystic Kidney Disease: 
Symptoms and Clinical Findings. 1984. Q J Med 53 (212): 511-22. 
 
Milutinovic, Jovan., Philip. J. Fialkow, Lawrence. Y. Agodoa, Leon. A. Phillips, Thomas. 
G. Rudd, and Susan. Sutherland. Clinical Manifestations of Autosomal Dominant 
Polycystic Kidney Disease in Patients Older Than 50 Years. 1990. Am J Kidney Dis 
15 (3): 237-43. 
 
Mitcheson, H. David, Gordon Williams, and John E. Castro. Clinical Aspects of 
Polycystic Disease of the Kidneys. 1977. Br Med J. 1 (6070): 1196-1199. 
 
Mushkin, Selma J., and Francis D. Collings. Economic Costs of Disease and Injury. 







Naitoh, Hiroshi, Hisanori Shoji, Isao Ishikawa, Reina Watanabe, Yuichi Furuta, Shigeru 
Tomozawa, Hiroaki Igarashi, Sachiko Shinozaki, Hideyuki Katsura, and Ryoichi 
Onozato. Intraductal Papillary Mucinous Tumor of the Pancreas Associated with 
Autosomal Dominant Polycystic Kidney Disease. 2005. J Gastrointest Surg 9 (6): 
843-5. 
 
National Institutes of Health, Bosutinib for Autosomal Dominant Polycystic Kidney 
Disease. 2011.  
http://clinicaltrials.gov/ct2/show/NCT01233869?term=polycystic+kidney+disease&r
ank=7 (accessed 11/24/2011). 
 
Nauli, Surya M, Francis J Alenghat, Ying Luo, Eric Williams, Peter Vassilev, Xiaogang 
Li, Andrew EH Elia, Weining Lu, Edward M Brown, and Stephen J Quinn. 
Polycystins 1 and 2 Mediate Mechanosensation in the Primary Cilium of Kidney 
Cells. 2003. Nat Genet 33 (2): 129-37. 
 
Nauta, Jeroen. Pathophysiology of Polycystic Kidney Disease: Experimental Studies. 
2000. Erasmus University Rotterdam. 
 
Nichols, Matthew T, Elsa Gidey, Tom Matzakos, Rolf Dahl, Greg Stiegmann, Raj J Shah, 
Jared J Grantham, J Gregory Fitz, and R Doctor Brian. Secretion of Cytokines and 
Growth Factors into Autosomal Dominant Polycystic Kidney Disease Liver Cyst 
Fluid. 2004. Hepatology 40 (4): 836-46. 
 
Nicolau, Carlos, Roser Torra, Luis Bianchi, Ramón Vilana, Rosa Gilabert, Alejandro 
Darnell, and Concepció Brú. Abdominal Sonographic Study of Autosomal Dominant 







O’Neill, W Charles, Michelle L Robbin, Kyongtae T Bae, Jared J Grantham, Arlene B 
Chapman, Lisa M Guay-Woodford, Vicente E Torres, Bernard F King, Louis H 
Wetzel, and Paul A Thompson. Sonographic Assessment of the Severity and 
Progression of Autosomal Dominant Polycystic Kidney Disease: The Consortium of 
Renal Imaging Studies in Polycystic Kidney Disease (Crisp). 2005. Am J Kidney Dis 
46 (6): 1058-64. 
 
Ong, Albert CM, and Peter C Harris. Molecular Pathogenesis of Adpkd: The Polycystin 
Complex Gets Complex. 2005. Kidney Int 67 (4): 1234-47. 
 
Parfrey, Patrick S, John C Bear, Janet Morgan, Benvon C Cramer, Patrick J 
McManamon, Mathew H Gault, David N Churchill, Manoj Singh, Richard Hewitt, 
and Stefan Somlo. The Diagnosis and Prognosis of Autosomal Dominant Polycystic 
Kidney Disease. 1990. N Engl J Med 323 (16): 1085-1090. 
 
Perrone, Ronald D. Development of Questions to Evaluate Endpoints in Kidney Disease : 
Polycystic Kidney Disease. In Patient-Reported Outcomes in Clinical Trials of 
Chronic Kidney Disease-Related Therapies 2010. 
 
Phillips, Lawrence H, Jack P Whisnant, W Michael O'Fallon, and Thoralf M Sundt. The 
Unchanging Pattern of Subarachnoid Hemorrhage in a Community. 1980. Neurology 
30 (10): 1034-1034. 
 
Pirson, Yves, and Dominique Chauveau. Cystic Disease of the Kidney. 1999 In Atlas of 
Diseases of the Kidney, edited by Richard J.  Glassock, Arthur H. Cohen and Jean 
Perre  Grünfeld, 2: Wiley-Blackwell. 
 
Pirson, Yves, Dominique Chauveau, and Vicente Torres. Management of Cerebral 
Aneurysms in Autosomal Dominant Polycystic Kidney Disease. 2002. J Am Soc 





Polycystic Kidney Disease Foundation. Polycystic Kidney Disease (Pkd) Information. 
2000. Kansas City. 
 
Pretorius, Dolores. H., M. Eugenia. Lee, Micheal. L. Manco-Johnson, Gail. R. Weingast, 
Aileen. B. Sedman, and Patricia. A. Gabow. Diagnosis of Autosomal Dominant 
Polycystic Kidney Disease in Utero and in the Young Infant. 1987. J Ultrasound Med 
6 (5): 249-55. 
 
Qian, Feng, Terry J. Watnick, Lewis F. Onuchic, and Gregory G. Germino. The 
Molecular Basis of Focal Cyst Formation in Human Autosomal Dominant Polycystic 
Kidney Disease Type I. 1996. Cell 87 (6): 979-87. 
 
Qian, Qi, Ming Li, Yiqiang Cai, Christopher J. Ward, Stefan Somlo, Peter C. Harris, and 
Vicente E. Torres. Analysis of the Polycystins in Aortic Vascular Smooth Muscle 
Cells. 2003. J Am Soc Nephrol 14 (9): 2280-2287. 
 
Rall, J. E., and Howard. M. Odel. Congenital Polycystic Disease of the Kidney; Review 
of the Literature and Data on 207 Cases. 1949. Am J Med Sci 218 (4): 399-407. 
 
Ravine, David, Robert N. Gibson, Rowan G. Walker, Leslie J. Sheffield, Priscilla 
Kincaid-Smith, and David M. Danks. Evaluation of Ultrasonographic Diagnostic 
Criteria for Autosomal Dominant Polycystic Kidney Disease 1. 1994. The Lancet 
343 (8901): 824-7. 
 
Reed, Berenice Y., Amirali Masoumi, Elwaleed Elhassan, Kim McFann, Melissa A. 
Cadnapaphornchai, David M. Maahs, Janet K. Snell-Bergeon, and Robert W. 
Schrier. Angiogenic Growth Factors Correlate with Disease Severity in Young 







Rice, Dorothy P. Cost-of-Illness Studies: Fact or Fiction? 1994. Lancet 344 (8936): 1519-
20. 
 
Rice, Dorothy P. Cost of Illness Studies: What Is Good About Them? 2000. Inj Prev 6 
(3): 177-9. 
 
Rice, Dorothy P., Thomas A. Hodgson, and Andrea N. Kopstein. The Economic Costs of 
Illness: A Replication and Update. 1985. Health Care Financ Rev 7 (1): 61-80. 
 
Robbins, James D., John J. Kim, Gary Zdon, Wing W. Chan, and Jason Jones. Resource 
Use and Patient Care Associated with Chronic Kidney Disease in a Managed Care 
Setting. 2003. J Manag Care Pharm 9 (3): 238-47. 
 
Rosenfield, Arthur. T., Mark. H. Lipson, Barry. Wolf, Kenneth. J. Taylor, Nancy. S. 
Rosenfield, and Ernesto. Hendler. Ultrasonography and Nephrotomography in the 
Presymptomatic Diagnosis of Dominantly Inherited (Adult-Onset) Polycystic Kidney 
Disease. 1980. Radiology 135 (2): 423-7. 
 
Rossetti, Sandro, Dominique Chauveau, Denise Walker, Anand Saggar-Malik, 
Christopher G Winearls, Vicente E Torres, and Peter C Harris. A Complete Mutation 
Screen of the Adpkd Genes by Dhplc. 2002. Kidney Int 61 (5): 1588-1599. 
 
Rossetti, Sandro, Lana Strmecki, Vicki Gamble, Sarah Burton, Vicky Sneddon, Belén 
Peral, Sushmita Roy, Aysin Bakkaloglu, Radovan Komel, and Christopher G 
Winearls. Mutation Analysis of the Entire Pkd1 Gene: Genetic and Diagnostic 








Ruggenenti, Piero, Andrea Remuzzi, Patrizia Ondei, Giorgio Fasolini, Luca Antiga, 
Bogdan Ene-Iordache, Giuseppe Remuzzi, and Franklin H. Epstein. Safety and 
Efficacy of Long-Acting Somatostatin Treatment in Autosomal-Dominant Polycystic 
Kidney Disease. 2005. Kidney Int 68 (1): 206-216. 
 
Saadi-Kheddouci, Sihem, Dominique Berrebi, Beatrice Romagnolo, Francoise Cluzeaud, 
Michel Peuchmaur, Axel Kahn, Alain Vandewalle, and Christine Perret. Early 
Development of Polycystic Kidney Disease in Transgenic Mice Expressing an 
Activated Mutant of the Beta-Catenin Gene. 2001. Oncogene 20 (42): 5972-81. 
 
Saburi, Sakura, Ian Hester, Evelyne Fischer, Marco Pontoglio, Vera Eremina, Manfred 
Gessler, Sue E Quaggin, Robert Harrison, Richard Mount, and Helen McNeill. Loss 
of Fat4 Disrupts Pcp Signaling and Oriented Cell Division and Leads to Cystic 
Kidney Disease. 2008. Nat Genet 40 (8): 1010-5. 
 
Sakurai, Yoichi, Mitsutaka Shoji, Toshiki Matsubara, Masahiro Ochiai, Takahiko 
Funabiki, Makoto Urano, Yoshikazu Mizoguchi, and Nobukazu Fuwa. Pancreatic 
Ductal Adenocarcinoma Associated with Potter Type Iii Cystic Disease. 2001. J 
Gastroenterol 36 (6): 422-8. 
 
Scheff, Robert T., Gary Zuckerman, Herschel Harter, James Delmez, and Robert Koehler. 
Diverticular Disease in Patients with Chronic Renal Failure Due to Polycystic 
Kidney Disease. 1980. Ann Intern Med 92 (2 Part 1): 202-204. 
 
Schievink, Wouter I, John III Huston, Vicente E Torres, and W Richard Marsh. 
Intracranial Cysts in Autosomal Dominant Polycystic Kidney Disease. 1995. J 






Schievink, Wouter I, Vicente E Torres, David G Piepgras, and David O Wiebers. 
Saccular Intracranial Aneurysms in Autosomal Dominant Polycystic Kidney Disease. 
1992. J Am Soc Nephrol 3 (1): 88-95. 
 
Schrier, Robert W, Kimberly K McFann, and Ann M Johnson. Epidemiological Study of 
Kidney Survival in Autosomal Dominant Polycystic Kidney Disease. 2003. Kidney 
Int 63 (2): 678-85. 
 
Schrier, Robert W. Renal Volume, Renin-Angiotensin-Aldosterone System, 
Hypertension, and Left Ventricular Hypertrophy in Patients with Autosomal 
Dominant Polycystic Kidney Disease. 2009. J Am Soc Nephrol 20 (9): 1888-93. 
 
Seeman, Tomáš, Jirí Dušek, Hana Vondrichová, Martin Kyncl, Ulrike John, Joachim 
Misselwitz, and Jan Janda. Ambulatory Blood Pressure Correlates with Renal 
Volume and Number of Renal Cysts in Children with Autosomal Dominant 
Polycystic Kidney Disease. 2003. Blood Press Monit 8 (3): 107-10. 
 
Seeman, Tomáš, Milan Sikut, Martin Konrad, Hana Vondřichová, Jan Janda, and Karl 
Schärer. Blood Pressure and Renal Function in Autosomal Dominant Polycystic 
Kidney Disease. 1997. Pediatr Nephrol 11 (5): 592-6. 
 
Segal, Arthur. J., Robery. F. Spataro, and Zoran. L. Barbaric. Adult Polycystic Kidney 
Disease: A Review of 100 Cases. 1977. J Urol 118 (5): 711-3. 
 
Segel, Joel E. Cost-of-Illness Studies—a Primer. 2006. RTI-UNC Center of Excellence in 
Health Promotion Economics. 
 
Shannon, M Brendan, Bruce L Patton, Scott J Harvey, and Jeffrey H Miner. A 
Hypomorphic Mutation in the Mouse Laminin Alpha5 Gene Causes Polycystic 





Sharp, Cindy K, Bernard E Zeligman, Ann M Johnson, Irene Duley, and Patricia A 
Gabow. Evaluation of Colonic Diverticular Disease in Autosomal Dominant 
Polycystic Kidney Disease without End-Stage Renal Disease. 1999. Am J Kidney 
Dis 34 (5): 863-868. 
 
Shefi, Shai, Jacob Levron, Andrei Nadu, and Gil Raviv. Male Infertility Associated with 
Adult Dominant Polycystic Kidney Disease: A Case Series. 2009. Archives of 
gynecology and obstetrics 280 (3): 457-460. 
 
Simon, H. B., and G. J. Thompson. Congenital Renal Polycystic Disease; a Clinical and 
Therapeutic Study of Three Hundred Sixty-Six Cases. 1955. J Am Med Assoc 159 
(7): 657-62. 
 
Simon, P., J. Y. Le Goff, K. S. Ang, C. Charasse, P. Le Cacheux, and G. Cam. 
[Epidemiologic Data, Clinical and Prognostic Features of Autosomal Dominant 
Polycystic Kidney Disease in a French Region]. 1996. Nephrologie 17 (2): 123-30. 
 
Smith, David H., Christina M. Gullion, Gregory Nichols, Douglas Scott Keith, and 
Jonathan Betz Brown. Cost of Medical Care for Chronic Kidney Disease and 
Comorbidity among Enrollees in a Large Hmo Population. 2004. J Am Soc Nephrol 
15 (5): 1300-1306. 
 
Sorenson, Christine M., Babu J. Padanilam, and Marc R. Hammerman. Abnormal 
Postpartum Renal Development and Cystogenesis in the Bcl-2 (-/-) Mouse. 1996. 
Am J Physiol 271 (1 Pt 2): F184-93. 
 
Stengel, Benedicte, Solenne Billon, Paul C. Van Dijk, Kitty J. Jager, Friedo W. Dekker, 
Keith Simpson, and J. Douglas Briggs. Trends in the Incidence of Renal 
Replacement Therapy for End-Stage Renal Disease in Europe, 1990-1999. 2003. 





Tarricone, Rosanna. Cost-of-Illness Analysis. What Room in Health Economics? 2006. 
Health Policy 77 (1): 51-63. 
 
Taylor, Donald H., Jr., and Frank A. Sloan. How Much Do Persons with Alzheimer's 
Disease Cost Medicare? 2000. J Am Geriatr Soc 48 (6): 639-46. 
 
Telenti, Amalio, Vicente E Torres, John B Jr Gross, Robert E Van Scoy, Manuel L 
Brown, and Robert R. Hattery. Hepatic Cyst Infection in Autosomal Dominant 
Polycystic Kidney Disease. 1990 Mayo Clinic Proc 65 (7): 933-42. 
 
Thanos, Anastasios, Antony Farmakis, and Nicolaos Davillas. Spontaneous Rupture of 
the Kidney: A Cause of Acute Abdominal Pain. Case Report. 1989. Scand J Urol 
Nephrol 23 (4): 313-4. 
 
Thompson, David, John Edelsberg, Karen L. Kinsey, and Gerry Oster. Estimated 
Economic Costs of Obesity to U.S. Business. 1998. Am J Health Promot 13 (2): 120-
7. 
 
Thomsen, Henrik S., Jan K. Madsen, Jorn H. Thaysen, and Karen Damgaard-Petersen. 
Volume of Polycystic Kidneys During Reduction of Renal Function. 1981. Urol 
Radiol 3 (2): 85-9. 
 
Torra, Roser, Celia Badenas, Jose L. San Millan, Laureano Perez-Oller, Xavier Estivill, 
and Alejandro Darnell. A Loss-of-Function Model for Cystogenesis in Human 









Torra, Roser, Joaquim Sarquella, Jordi Calabia, Jordi Martí, Elisabet Ars, Patricia 
Fernández-Llama, and Jose Ballarin. Prevalence of Cysts in Seminal Tract and 
Abnormal Semen Parameters in Patients with Autosomal Dominant Polycystic 
Kidney Disease. 2008. Clin J Am Soc Nephrol 3 (3): 790-793. 
 
Torres, Vicente . E., Stephen. B. Erickson, Lynwood. H. Smith, David. M. Wilson, 
Robert. R. Hattery, and Joseph. W. Segura. The Association of Nephrolithiasis and 
Autosomal Dominant Polycystic Kidney Disease. 1988. Am J Kidney Dis 11 (4): 
318-325. 
 
Torres, Vicente E., Yiquiang Cai, X. I. Chen, Guanquing Q. Wu, L. I. N. Geng, Kathleen 
A. Cleghorn, Christopher M. Johnson, and Stefan Somlo. Vascular Expression of 
Polycystin-2. 2001. J Am Soc Nephrol 12 (1): 1-9. 
 
Torres, Vicente E., Peter C. Harris, and Yves Pirson. Autosomal Dominant Polycystic 
Kidney Disease. 2007. The Lancet 369 (9569): 1287-1301. 
 
Torres, Vicente E., Douglas S. Keith, Kenneth P. Offord, Sui P. Kon, and David M. 
Wilson. Renal Ammonia in Autosomal Dominant Polycystic Kidney Disease. 1994. 
Kidney Int 45 (6): 1745-53. 
 
Torres, Vicente E., Esther Meijer, Kyongtae T. Bae, Arlene B. Chapman, Olivier 
Devuyst, Ron T. Gansevoort, Jared J. Grantham, Eiji Higashihara, Ronald D. 
Perrone, Holly B. Krasa, John J. Ouyang, and Frank S. Czerwiec. Rationale and 
Design of the Tempo (Tolvaptan Efficacy and Safety in Management of Autosomal 
Dominant Polycystic Kidney Disease and Its Outcomes) 3-4 Study. 2011. Am J 








Torres, Vicente E., David M. Wilson, John C. Burnett, Jr., Christopher M. Johnson, and 
Kenneth P. Offord. Effect of Inhibition of Converting Enzyme on Renal 
Hemodynamics and Sodium Management in Polycystic Kidney Disease. 1991. Mayo 
Clin Proc 66 (10): 1010-7. 
 
Torres, Vicente. E., Kathleen A. Donovan, Gloria Scicli, Keith E. Holley, Stephen N. 
Thibodeau, Oscar A. Carretero, Tadashi Inagami, James A. McAteer, and 
Christopher M. Johnson. Synthesis of Renin by Tubulocystic Epithelium in 
Autosomal-Dominant Polycystic Kidney Disease. 1992. Kidney Int 42 (2): 364-73. 
 
Torres, Vicente. E., and Peter. C. Harris. Autosomal Dominant Polycystic Kidney 
Disease: The Last 3 Years. 2009. Kidney Int 76 (2): 149-68. 
 
Torres, Vicente. E., Sanjeev. Rastogi, Bernard. F. King, Anthony. W. Stanson, John. B. 
Gross, and David. M. Nogorney. Hepatic Venous Outflow Obstruction in Autosomal 
Dominant Polycystic Kidney Disease. 1994. J Am Soc Nephrol 5 (5): 1186-1192. 
 
Torres, Vincente E., and Jared J. Grantham. Cystic Diseases of the Kidney. 2007 In 
Brenner and Rector's the Kidney, edited by B.M. Brenner. Philadelphia, PA: 
Saunders Elsevier. 
 
Trudel, Marie, Vivette D'Agati, and Frank Costantini. C-Myc as an Inducer of Polycystic 
Kidney Disease in Transgenic Mice. 1991. Kidney Int 39 (4): 665-71. 
 
United States Renal Data System. Usrds 2011 Annual Data Report: Esrd Reference 







United States Renal Data System. Usrds 2012 Annual Data Report: Incidence, 
Prevalence, Patient Characteristics, and Treatment Modalities. 2012. Bethesda: NIH, 
National Institute of Diaetes and Digestive and Kidney Diseases. 
 
Vecchi, Maurizio Li, Paola Cianfrone, Rocco Damiano, and Giorgio Fuiano. Infertility in 
Adults with Polycystic Kidney Disease. 2003. Nephrol Dial Transplant 18 (1): 190-
191. 
 
Wakai, Kenji, Shigeru Nakai, Kenjiro Kikuchi, Kunitoshi Iseki, Naoko Miwa, Ikuto 
Masakane, Atsushi Wada, Takahiro Shinzato, Yuji Nagura, and Takashi Akiba. 
Trends in Incidence of End-Stage Renal Disease in Japan, 1983-2000: Age-Adjusted 
and Age-Specific Rates by Gender and Cause. 2004. Nephrol Dial Transplant 19 (8): 
2044-52. 
 
Walz, Gerd, Klemens Budde, Marwan Mannaa, Jens Nürnberger, Christoph Wanner, 
Claudia Sommerer, Ulrich Kunzendorf, Bernhard Banas, Walter H. Hörl, Nicholas 
Obermüller, Wolfgang Arns, Hermann Pavenstädt, Jens Gaedeke, Martin Büchert, 
Christoph May, Harald Gschaidmeier, Stefan Kramer, and Kai-Uwe Eckardt. 
Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease. 2010. 
N Engl J Med 363 (9): 830-840. 
 
Watson, Micheal L., Ann M. Macnicol, Paul L. Allan, and Alan F. Wright. Effects of 
Angiotensin Converting Enzyme Inhibition in Adult Polycystic Kidney Disease. 
1992. Kidney Int 41 (1): 206-10. 
 
Wei, Wan-Hui, Viorica Popov, Jerzy A. Walocha, Jie Wen, and Elsa Bello-Reuss. 
Evidence of Angiogenesis and Microvascular Regression in Autosomal-Dominant 







Wijdicks, Eelco F. M., Vicente E. Torres, and Wouter I. Schievink. Chronic Subdural 
Hematoma in Autosomal Dominant Polycystic Kidney Disease. 2000. Am J Kidney 
Dis 35 (1): 40-43. 
 
Wilson, Patricia D. Polycystic Kidney Disease. 2004. N Engl J Med 350 (2): 151-64. 
 
Wiseman, Virginia, and Gavin Mooney. Burden of Illness Estimates for Priority Setting: 
A Debate Revisited. 1998. Health Policy 43 (3): 243-51. 
 
Wong, Hubert, Laura Vivian, Gabrielle Weiler, and Guido Filler. Patients with 
Autosomal Dominant Polycystic Kidney Disease Hyperfiltrate Early in Their 
Disease. 2004. Am J Kidney Dis 43 (4): 624-628. 
 
Yersin, Claude, Pascal Bovet, Jean-Pierre Wauters, Daniel F. Schorderet, Gregory Pescia, 
and Fred Paccaud. Frequency and Impact of Autosomal Dominant Polycystic Kidney 
Disease in the Seychelles (Indian Ocean). 1997. Nephrol Dial Transplant 12 (10): 
2069-74. 
 
Zhao, Xiao, Andrew D. Paterson, Alireza Zahirieh, Ning He, Kairong Wang, and York 
Pei. Molecular Diagnostics in Autosomal Dominant Polycystic Kidney Disease: 







An observational database analysis was conducted using information from a large 
administrative database.  Individuals 18 years old or older with autosomal dominant PKD 
(ADPKD) were identified using International Classification of Disease, 9th Revision, 
Clinical Modification (ICD-9-CM) codes.  Administrative claims data were used to 
calculate annual all-cause health care resource utilization for hospitalizations, hospital 
days, nursing home confinements, nursing home days, emergency department visits and 
outpatient visits.  All-cause heath care expenditures among individuals with ADPKD 
were characterized based on whether they were for hospital, nursing home, outpatient, 
emergency room or prescription services.  A one-year study interval from April 1, 2011 
through March 31, 2012 was used in the analysis.   
Data Source 
Health insurance claims data from a large administrative claims database between 
April 1, 2011 and March 31, 2012 were used for the study.  The database included 
medical and pharmacy claims for 13 million privately-insured lives covering all census 






Institutional Review Board approval for the study was obtained from the 
Committee on the Use of Human Subjects in Research at Purdue University, West 
Lafayette, Indiana. 
Study Sample 
Analytic samples were drawn based on each study objective.  The inclusion 
criteria and exclusion criteria for each analytic sample are described below. 
Prevalence of ADPKD 
Individuals 18 years of age or older and enrolled in a tracked health plan anytime 
during  the period from April 1, 2011 through March 31, 2012, were eligible for inclusion 
in the sample for determination of ADPKD prevalence.  No exclusion criteria were 
specified for this prevalence sample. 
All-Cause Health Care Resource Utilization and Expenditures 
Individuals 18 years of age or older, enrolled in a tracked health plan for twelve 
months in the period from April 1, 2011 through March 31, 2012, and having an ICD-9-
CM diagnosis code for “polycystic kidney, autosomal dominant” (753.13) or for 
“polycystic kidney, unspecified type (753.12) were eligible for inclusion in the analytic 
sample.  Persons having ICD-9-CM diagnosis codes for “polycystic kidney, autosomal 





Incremental Health Care Resource Utilization and Expenditures 
The sample for analysis of incremental health care utilization and expenditures 
used the same inclusion and exclusion criteria as the one for all-cause analysis.  
Individuals 18 years of age or older, enrolled in a tracked health plan for twelve months 
in the period from April 1, 2011 through March 31, 2012, and having an ICD-9-CM 
diagnosis code for “polycystic kidney, autosomal dominant” (753.13) or for “polycystic 
kidney, unspecified type (753.12) were eligible for inclusion in the analytic sample.  
Persons having ICD-9-CM diagnosis codes for “polycystic kidney, autosomal recessive” 
(753.14) or “cystic kidney disease” (753.1) were excluded from the analytic sample. 
This sample was linked to comparison individuals without ADPKD on age and 
gender.  To be included in the non-PKD group, an individual had to be 18 years of age or 
older by April 1, 2011 and enrolled in a tracked health plan for twelve months between 
April 1, 2011 through March 31, 2012.  Exclusion criteria for the comparison group were 
having “polycystic kidney, autosomal recessive” (753.14) or “cystic kidney disease” 
(753.1), chronic kidney disease stage three to stage six (585, 585.3, 585.4, 585.5, 585.6, 
585.9, 586), nephrotic syndrome (581, 581.0, 581.1, 581.2, 581.3, 581.8, 581.9, 581.81, 
583.81, V13.03), diabetic kidney disease (250.4, 250.40, 250.41, 250.42, 250.43, 249.4, 
249.40, 249.41), or kidney stones associated with cystic kidney disease (diagnosis code: 






All-Cause Health Care Resource Utilization 
All-cause health care resource utilization among persons with ADPKD was 
estimated from patients’ insurance claims during the period from April 1, 2011 through 
March 31, 2012, for number of hospitalizations, hospital days, nursing home 
confinements, nursing home days, outpatient visits and emergency room visits.  Total 
number of hospitalizations and nursing home stays were determined by identifying and 
counting the number of unique confinements per patient.  Claims for outpatient facilities 
or emergency rooms were identified by the place of service and provider category 
associated with the claim. Each visit to an outpatient facility or emergency room had a 
unique claim identification number, and multiple claims from the same visit were had a 
claim sequence number each.  In the first step, sub-claims were collapsed such that each 
visit had only record.  One visit at an outpatient facility or an emergency room was 
defined as a summation of all visits to that facility per day.  For example, if a patient 
visited his primary physician’s office three times in one day and on the same day, visited 
a particular laboratory twice, the resultant visit count for that day was one visit each for a 
physician office and for a laboratory.  The total number of visits per patient for 





All-Cause Health Care Expenditures 
All-cause heath care expenditures among individuals with ADPKD were 
characterized based on whether they are for hospital, nursing home, outpatient, 
emergency room, or prescription services during the one year period from April 1, 2011 
through March 31, 2012.  To account for pricing variation across providers or geographic 
regions, standard prices in the database reflected allowed payments from a single source 
with a consistent payment plan.  The standardized prices have been used in analysis of 
expenditures reported in prior literature (Kimball et al. 2011; Vekeman et al. 2011).  
For inpatient expenditures, standard cost of the inpatient admission as a whole 
were added to professional fees associated with the confinement, but billed externally.  
Total hospitalization costs per patient were calculated by adding expenditures from all 
general hospital episodes.  Total nursing home expenditures per patient were calculated 
by summing expenditures from all nursing home confinements.  In this study, sub-claims 
were collapsed such that each visit to an emergency room or an outpatient facility per day 
was represented by a single record.  If there were multiple visits to the same facility on 
the same day, a visit-level summation of expenditures was generated to obtain one record 
per visit (outpatient facility or emergency room ) per day.  Total annual emergency room 
expenditures as well as total annual outpatient expenditures per patient were calculated 
by adding facility-specific expenditures for the patient in the specified one-year period.  
Total annual prescription expenditures per patient, were calculated by adding standard 






Demographic variables used in the study included age, gender and geographical 
region.  Gender was coded as female or male.  Geographical region were classified into 
four regions including Midwest, Northeast, South and West. 
Clinical Variables 
Charlson Comorbidity Index 
The Charlson Comorbidity Index consists of eighteen categories of comorbidity, 
which are defined using ICD-9 diagnosis codes.  Higher comorbidity scores indicated a 
more severe burden of comorbidity.  A modified Charlson comorbidity index developed 
by Romano et al. was constructed in which renal diseases were excluded in the 
computation of comorbidity index scores was calculated for each individual, based on 
claims between April 1, 2011 through March 31, 2012 (Romano, Roos, and Jollis 1993).   
Cardiovascular Disease 
 The presence of cardiovascular disease in the sample was defined by 
administrative claims with corresponding ICD-9 diagnosis codes for angina pectoris, 
myocardial infarction, congestive heart failure or stroke/transient ischemic attack during 
the one year period from April 1, 2011 through March 31, 2012.  The list of codes for 
cardiovascular disease were obtained from an online searchable 2009 ICD-9-CM and 






 The presence of diabetes in the sample was defined by administrative claims with 
corresponding ICD-9 diagnosis codes for Type 1 diabetes mellitus, Type 2 diabetes 
mellitus or gestational diabetes during the one year period from April 1, 2011 through 
March 31, 2012.  The list of codes for diabetes were obtained from an online searchable 
2009 ICD-9-CM and Medical Terminology dictionary (Anonymous 2009). 
Statistical Analysis 
Data were analyzed using SAS for Unix Version 9.2 and STATA for Unix version 
12.    An a priori alpha level of 0.05 was used in all statistical analysis.  Frequency 
distributions were developed and Chi-square tests were used to assess statistical 
differences between persons with or without ADPKD on demographic variables and 
clinical variables including age, gender, geographical region, Charlson Comorbidity 
Index (Charlson et al. 1987), cardiovascular disease and diabetes.  Multivariate models in 
this study were adjusted for geographical region because of prior reports of variation in 
health care utilization and spending in different health care markets, above and beyond 
observable differences in demographics or disease severity (Philipson et al. 2010).   
Statistical analyses for each objective are explained in the sections below. 
Prevalence of ADPKD 
The number of individuals 18 years or older with ICD-9 diagnosis codes for 





type” (753.12), and enrolled anytime during the period from April 1, 2011 through March 
31, 2012, were identified and divided by the total population of covered individuals 18 
years or older, during the same one year period.  A 95 percent confidence interval of the 
estimated prevalence was constructed.   
All-Cause Health Care Resource Utilization  
All-cause heath care resource utilization among individuals with ADPKD were  
characterized by number of hospitalizations, hospital days, nursing home confinements, 
nursing home days, outpatient visits and emergency room visits, during the one year 
period from April 1, 2011 through March 31, 2012.  Unadjusted means, medians and 95 
percent confidence intervals were computed for each utilization category.  Wilcoxon 
Mann Whitney tests were used to detect differences between individuals with ADPKD 
and those without ADPKD, for each resource utilization variable. 
All-Cause Health Care Expenditures  
All-cause heath care expenditures among individuals with ADPKD were 
characterized for hospitals, nursing homes, outpatient services, emergency rooms, and 
prescription services during the one year period from April 1, 2011 through March 31, 
2012.  To account for pricing variation across providers or geographic regions, the 
database included standard prices that reflected allowed payments from a single source 
with a consistent payment plan.  Unadjusted means, medians and 95 percent confidence 





were used to detect differences between individuals with ADPKD and those without 
ADPKD, for each expenditure variable. 
Incremental Health Care Resource Utilization Associated with ADPKD 
Each individual with ADPKD was linked one-to-one based on age and gender 
with comparison individuals without PKD for estimation of incremental annual health 
care resource utilization associated with ADPKD.  A systematic approach based on 
examination of data distributional characteristics and assessment of fit of alternative 
models was used to select a multivariate model for analysis.  Residuals of ordinary least 
squares regression models with untransformed and models with log transformed 
utilization and expenditure variables were examined for violation of assumptions.  P-
values lower than 0.05 for each Kolmogorov-Smirnov test were used to assess whether 
residuals were normally distributed (D'Agostino and Stephens 1986).  Glejser tests were 
used to investigate whether residuals were significantly associated with independent 
variables (Glejser 1969).  Generalized linear models were also developed and tested for 
model fit.  Presence of overdispersion of dependent variables was assessed using Vuong 
tests (Long and Freese 2006; Vuong 1989), and likelihood ratio tests and the z-test for 
alpha were used to determine comparative fit of alternative generalized linear models 
(Long and Freese 2006; Vuong 1989; Cameron and Trivedi 1986)    
Individual regression models were developed to estimate independent association 
between ADPKD and utilization of health services such that individual models were 
developed for hospitalizations, hospital days, nursing home confinements, nursing home 





ADPKD was included in each model and covariates in each model included age, gender, 
co-morbidity index score, cardiovascular disease, diabetes and geographical region, to 
adjust for those risk factors.  The general regression model developed for estimating 
incremental health care resource utilization is shown below: 
 
Resource Utilization = β0 + β1 ADPKD + β2 Age + β3 Gender 
        + β4 Cardiovascular Disease + β5 Diabetes + β6 Geographical Region (Midwest)  +  
        + β7 Geographical Region (West) + β8 Geographical Region (South)  + ε   
 
where, “Resource Utilization” is the dependent variable for a type of health care resource 
utilization including hospitalizations, hospital days, nursing home confinements, nursing 
home days, outpatient visits, or emergency room visits.  “ADPKD” is a binary variable 
with a value of ‘1’ for persons with ADPKD and ‘0’ for persons without ADPKD.  ‘Age’ 
is a continuous variable that represents the age of the individual.  “Gender” is a binary 
variable with a value of ‘1’ for males and ‘0’ for females.  “Cardiovascular Disease” is a 
binary variable with a value of ‘1’ for persons with cardiovascular disease and ‘0’ for 
persons without cardiovascular disease.  “Diabetes” is a binary variable with a value of 
‘1’ for persons with diabetes and ‘0’ for persons without diabetes. “Geographical Region 
(Midwest)”, Geographical Region (West) and Geographical Region (South) are dummy 
variables for geographical region.   ‘ε’ is the error term and incremental resource 
utilization associated with the disease is the estimate of the parameter β1, which is the 





Incremental Health Care Expenditures Associated with ADPKD 
For analysis of incremental health care expenditures associated with ADPKD, 
regression models similar to those developed for analysis of incremental resource 
utilization were developed.  A systematic approach, similar to that used for selecting a 
model for estimating incremental resource utilization, based on examination of data 
distributional characteristics and assessment of fit of alternative models, was used to 
select a multivariate model for analysis of incremental expenditures.  Individual 
regression models were developed to estimate independent association between ADPKD 
and total expenditures, hospital expenditures, nursing home expenditures, outpatient 
expenditures, emergency room expenditures, and medication expenditures.  A binary 
predictor variable for ADPKD was included in each model.  Covariates in each model 
included age, gender, co-morbidity index, cardiovascular disease, diabetes and 
geographical region, to adjust for any differences between the ADPKD group and the 
comparison group without ADPKD.  The formula for the general regression model 
developed for estimating incremental health care expenditures is given below: 
 
Expenditure Category = β0 + β1 ADPKD + β2 Age + β3 Gender 
        + β4 Cardiovascular Disease + β5 Diabetes + β6 Geographical Region (Midwest)  +  
        + β7 Geographical Region (West) + β8 Geographical Region (South)  + ε   
 
where, “Expenditure Category” is the dependent variable for a type of health care 





expenditures, outpatient expenditures, emergency room expenditures, or medication 
expenditures.  “ADPKD” is a binary variable with a value of ‘1’ for persons with 
ADPKD and ‘0’ for persons without ADPKD.  ‘Age’ is a continuous variable that 
represents the age of the individual.  “Gender” is a binary variable with a value of ‘1’ for 
males and ‘0’ for females.  “Cardiovascular Disease” is a binary variable with a value of 
‘1’ for persons with cardiovascular disease and ‘0’ for persons without cardiovascular 
disease.  “Diabetes” is a binary variable with a value of ‘1’ for persons with diabetes and 
‘0’ for persons without diabetes.  “Geographical Region (Midwest)”, “Geographical 
Region (West)”, and “Geographical Region (South)” are dummy variables for 
geographical region.   ‘ε’ is the error term and incremental expenditure associated with 
the disease is the estimate of the parameter β1, which is the regression coefficient of the 
independent variable “ADPKD”.   
Sub-Group Analysis by whether Diagnosed with End-Stage Renal Disease 
Sub-group analysis examined incremental resource utilization and expenditures 
associated with ADPKD across two sub-groups.  ADPKD cases with a diagnosis of end-
stage renal disease (ICD-9-CM code 586.6) and their linked comparison observations 
were one sub-group and cases without end-stage renal disease and their linked 
comparison observations formed the other sub-group.  Individual regression models, as 
described for the overall analysis, were developed to estimate incremental resource 
utilization and expenditures by category for each sub-group adjusting for risk factors 
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Prevalence of ADPKD 
Figure 1 shows the sample selection procedure and results for selection of the 
sample for determining prevalence of ADPKD.  There were 10,500,664 persons at least 
18 years old and enrolled during the period from April 1, 2011 through March 31, 2012.  
Of those10,500,664 persons, 5,878 individuals satisfied sample selection criteria of being 
at least 18 years old, enrolled anytime during the 12-month period from April 1, 2011 
through March 31, 2012 and having an ICD-9-CM diagnosis code for “polycystic kidney, 
autosomal dominant” (753.13) or for “polycystic kidney, unspecified type (753.12).  The 
prevalence of autosomal dominant PKD was one in 1,786 persons or 560 cases per 
million population.  The 95 percent confidence interval for estimated prevalence was 
1,742 to 1,833. 
Demographic Characteristics of Prevalence Sample  
Table 1 shows characteristics of the prevalence sample and compares it to the 
total population covered by the administrative database.  In the prevalence sample, 81.9 
percent of individuals with ADPKD were 35 years of age older.  The proportion of 
females with ADPKD (53%) was higher than males with ADPKD (47%).  The proportion 







Figure 1. Sample Selection Results to Determine ADPKD Prevalence
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Table 1. Demographic Characteristics of Prevalence Sample  
 ___________________________________________________________________________________________________________  
  With ADPKD Total Covered Population  
  (n=5,878) (n=10,494,786)  
  ________________________  ______________________  
 Characteristic Number (Percent) Number (Percent) p-valuea 
 ____________________________________________________________________________________________________________ 
Age  
 Under 35 1,062 (18.1) 3,546,924  (33.8)  <0.001 
 35 to 44 1,206 (20.5) 2,271,320  (21.6) 0.036 
 45 to 54 3,060 (52.0) 4,083,630 (38.9) <0.001 
 65 and over 550  (9.4) 591,912  (5.6) <0.001  
 
Gender  
 Female 3,116  (53.0) 5,271,621  (50.2) <0.001  
 Male 2,762 (47.0) 5,222,341 (49.8) <0.001 
 Missing/Unknown -  824 (0.0) - 
 
Region 
 Midwest 1,550  (26.4) 2,722,158  (25.9) 0.45  
 Northeast 607 (10.3) 1,046,279 (10.0) 0.36  
 South 2,760  (47.0) 4,914,171  (46.8) 0.84  
 West 960  (16.3) 1,805,781 (17.2) 0.075 
 Missing/Unknown -  6,398 (0.1) - 
 ____________________________________________________________________________________________________________ 







was no difference in the proportions of individuals with ADPKD versus the proportion of 
individuals in the population by geographical region.    
All-Cause Resource Utilization and Expenditures 
Sample Characteristics 
Figure 2 shows the sample selection procedure and results for selection of the 
sample for determining all-cause resource utilization and expenditures as well as for 
determining incremental resource utilization and expenditures.  Out of 10,500,664 
persons covered in the database, 4,020 individuals satisfied sample selection criteria of 
being at least 18 years old, enrolled continuously for the 12-month period from April 1, 
2011 through March 31, 2012 and having a diagnosis for autosomal dominant PKD.  
After excluding 115 individuals who either had a diagnosis of autosomal recessive PKD 
or unspecified cystic kidney disease, and 61 persons who had no medical claim 
information, a total of 3,844 individuals remained in the ADPKD group.   The individuals 
with a diagnosis for ADPKD were linked one-to-one with individuals without ADPKD, 
resulting in 3,844 persons in the comparison group and a total of 7,688 persons in the 
sample for determining all-cause resource utilization and expenditures and determining 
incremental resource utilization and expenditures.  Sample characteristics are described 








Figure 2. Sample Selection Results to Determine All-Cause and Incremental Health Care Resource Utilization and Expenditures 
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Table 2 shows that approximately 55 percent of the sample was between 45 to 64  
years old.  Since persons with ADPKD were linked one-to-one on age with a comparison 
sample of persons without ADPKD, no significant differences were observed on age 
between persons with ADPKD and those without ADPKD.  The mean age of the sample 
was 49.15 years with a standard deviation of 13.67.   
Gender 
Table 3 shows sample distribution based on gender.  The proportion of females 
with ADPKD was higher (53.2%) than males with ADPKD (46.8%).  Since persons with 
ADPKD were linked one-to-one on gender with a comparison sample of persons without 
ADPKD, no significant gender differences were observed between person with ADPKD 
and those without ADPKD.  
Charlson comorbidity Index 
Table 4 describes the distribution of the study sample and compares persons with 
ADPKD and those without ADPKD with respect to Charlson Comorbidity Index scores.  
Fifty-three percent of the sample had a Charlson comorbidity score of zero indicating that 
they did not have any of the comorbid conditions listed in the Charlson Comorbidity 
Index, other than renal diseases, which were excluded from the algorithm for calculating 





the sample had a score of two.  Individuals with a score of three or more constituted 17.1 
percent of the sample.  
Among individuals with ADPKD, 44.2 percent had a Charlson comorbidity score 
of zero indicating that they did not have any of the comorbid conditions listed in the 
Charlson Comorbidity Index.  In comparison, a significantly higher proportion of 
individuals in the comparison group without ADPKD (62.5%) had Charlson Comorbidity 
Index scores greater than zero indicating that persons with ADPKD had more 
comorbidities compared to persons without ADPKD.  Significantly higher proportions 
were observed for individuals in the ADPKD group for each level of Charlson 
Comorbidity Index score above zero, compared to the those individuals without ADPKD, 
for a Charlson score of ‘1’ (20.3 percent vs. 17.3 percent, p=0.003), for a Charlson score 
of ‘2’ (12.1 percent vs. 9.3 percent, p=0.003), for a Charlson score of ‘3’ (8.1 percent vs. 
4.7 percent, p<0.001), for a Charlson score of ‘4’ (5.0 percent vs. 2.3 percent, p<0.001), 
for a Charlson score of ‘5’ (3.1 percent vs. 1.3 percent, p<0.001), and also for a Charlson 
score of ‘6 or more’ (7.2 percent vs. 2.6 percent, p<0.001). 
Cardiovascular Disease 
The sample distribution based on presence of cardiovascular disease is shown in 
Table 5.  Cardiovascular disease was present 19.4 percent of the overall sample.  Among 
persons with ADPKD, a total of 983 persons or 25.6 percent had a diagnosis of 
cardiovascular disease.  This proportion was significantly higher than for persons without 






The sample distribution based on presence of diabetes is shown in Table 5.  
Diabetes was present in a total of 926 persons or 19.4 percent of the overall sample.  
Among persons with ADPKD, 14.1 percent had a diagnosis of diabetes, which was 
significantly higher than among persons without ADPKD, where 10.0 percent had with 
diabetes.  
Geographical Region 
Table 6 shows the distribution of the sample by geographical region.  The sample 
was divided into four regions including the Midwest, Northeast, South and West.  The 
largest proportion of the sample was from the South (44.9 percent), followed by the 
Midwest (27.2 percent) and the West (17.4 percent).  Among persons with ADPKD, a 
total of 1,777 persons or 46.2 percent were from the South.  The proportion of individuals 
from the comparison group without ADPKD from the South was not significantly 
different, 43.7 percent.  Similarly, there were no differences observed in the proportion of 
ADPKD patients by geographical region when compared to the proportion of persons 
without ADPKD from the Midwest, Northeast or the West. 
ADPKD Complications 
The presence of specific ADPKD complications including liver cysts, kidney 
stones, urinary tract infection or cerebral aneurysm during the period from April 1, 2011 





Table 2. Distribution of Study Sample by Age (n=7,688) 
 ______________________________________________________________________  
   Number 
Age  (n=7,688) Percent 
 ______________________________________________________________________  
Under 35  1,242 16.2 
 
35 to 44 1,496 19.5 
 
45 to 54 2,086 27.1 
 
55 to 64 2,118 27.5 
 
65 and over 746 9.7  
 ______________________________________________________________________  





Table 3. Distribution of Study Sample by Gender (n=7,688) 
 ______________________________________________________________________  
   Number 
Gender (n=7,688) Percent 
 ______________________________________________________________________  
Female  4,094 53.2 
 
Male  3,594 46.8 





Table 4. Distribution of Total Study Sample and Distribution of Persons with or without ADPKD by Charlson Comorbidity Index 
 ____________________________________________________________________________________________________________ 
  Total Sample With ADPKD Without ADPKD   
  (n=7,688) (n=3,844) (n=3,844) 
  ________________ ________________________ _________________________  
Charlson Number (Percent) Number (Percent) Number (Percent) p-valuea  
Comorbidity Index 
 ____________________________________________________________________________________________________________ 
 0 4,103 (53.4) 1,700  (44.2) 2,403  (62.5) <0.001 
 
 1 1,447 (18.8) 781  (20.3) 666  (17.3) 0.003 
 
 2 823 (10.7) 464  (12.1) 359  (9.3) 0.003 
 
 3 491 (6.4) 312  (8.1) 179  (4.7) <0.001 
 
 4 280 (3.6) 192  (5.0) 88  (2.3) <0.001 
 
 5 169 (2.2) 120  (3.1) 49  (1.3) <0.001 
 
 6 or more 375 (4.9) 275  (7.2) 100  (2.6) <0.001 
 ____________________________________________________________________________________________________________ 







Table 5. Distribution of Total Study Sample and Distribution of Persons with or without ADPKD 
 by Presence of Cardiovascular Disease and Presence of Diabetes 
 ____________________________________________________________________________________________________________ 
  Total Sample With ADPKD Without ADPKD   
  (n=7,688) (n=3,844) (n=3,844) 
  ________________ ________________________ _________________________  
 Disease Number (Percent) Number (Percent) Number (Percent) p-valuea  
 ____________________________________________________________________________________________________________ 
Cardiovascular disease 1,493 (19.4) 983  (25.6) 510  (13.3) <0.001 
  
Diabetes 926 (12.0) 542  (14.1) 384  (10.0) <0.001 
 ____________________________________________________________________________________________________________ 







Table 6. Distribution of Total Study Sample and Distribution of Persons with or without ADPKD by Geographical Region 
 ____________________________________________________________________________________________________________ 
  Total Sample With ADPKD Without ADPKD   
  (n=7,688) (n=3,844) (n=3,844) 
  ________________ ________________________ _________________________  
 Region Number (Percent) Number (Percent) Number (Percent) p-valuea  
 ____________________________________________________________________________________________________________ 
Midwest 2,101 (27.2) 1,008  (26.2) 1,093  (28.4) 0.063 
 
Northeast 801 (10.4) 419  (10.9) 382  (10.0) 0.190 
  
South 3,455 (44.9) 1,777  (46.2) 1,678  (43.7) 0.092 
 
West 1,327 (17.4) 640  (16.7) 687 (17.9) 0.190 
 ____________________________________________________________________________________________________________ 







Table 7. Number of Complications among Persons with ADPKDa 
 ______________________________________________________________________  
   Number 
Number of Complications (n=3,844) Percent 
 ______________________________________________________________________  
  0  2,937 76.4  
 
  1 776 20.1 
 
  2 127 3.3 
 
  3 7 0.2 
 
  4 0 0 
 ______________________________________________________________________  
a Number of ADPKD complications, including liver cysts, kidney stones, urinary tract 
infection or cerebral aneurysm, ranging from 0 (no ADPKD complication) to 4 (up to 






Table 8. Disease Complications among Persons with ADPKDa 
 ___________________________________________________________________________ 
 Absence of Complication Presence of Complication 
 ______________ _______________ 
ADPKD Complication Number (Percent) Number (Percent) 
 ___________________________________________________________________________ 
Liver cysts 3,747 (97.5) 97  (2.5) 
 
Kidney stones 3,532  (91.9) 312 (8.1)  
  
Urinary tract infection 3,238  (84.2) 606 (15.6)  
  
Cerebral aneurysm 3,808  (99.1) 36 (0.9) 
 ___________________________________________________________________________ 






medical claims.  Table 7 shows the number of complications among persons with 
ADPKD.  There were 2,937 persons or 76.4 percent of persons with ADPKD who did not 
did not have any ADPKD complications.  There were 776 persons or 20.1 percent of 
ADPKD patients who had at least one ADPKD complication.   Individuals with two or 
more ADPKD complications constituted only 3.5 percent of the sample.  
The frequencies of persons with specific ADPKD complications are reported in Table 8.  
A total of 606 persons or 15.6 percent of persons with ADPKD were diagnosed with 
urinary tract infection in the one year study period.  Urinary tract infection was the most 
common ADPKD complication observed followed by kidney stones (8.1 percent) and 
liver cysts (2.5 percent).  Less than one percent of the persons with an ADPKD diagnosis 
had a diagnosis of cerebral aneurysm. 
End-Stage Renal Disease 
The presence of end-stage renal disease among persons with ADPKD was 
identified based on the ICD-9-CM diagnosis code (586.6) coding for end-stage renal 
disease.  Out of 3,844 persons with ADPKD, 644 had end-stage renal disease whereas the 
remaining 3,200 persons with ADPKD had not reached end-stage renal disease.  
Unadjusted Annual Health Care Resource Utilization 
Mean unadjusted annual health care utilization for persons with or without 
ADPKD is reported in Table 9.  Mean annual unadjusted hospitalizations among 





unadjusted hospital days among individuals with ADPKD were 2.0 (95 percent C.I.: 1.6 
to 2.5).   Among individuals with ADPKD, mean annual unadjusted nursing home 
confinements were 0.011 (95 percent C.I.: 0.0077 to 0.015) and the mean annual 
unadjusted nursing home length of stay was 0.33 (95 percent C.I.: 0.18 to 0.49).   Mean 
annual unadjusted outpatient visits among individuals with ADPKD were 21.1 (95 
percent C.I.: 20.3 to 21.9).   Mean annual unadjusted emergency room visits among 
individuals with ADPKD were 1.0 (95 percent C.I.: 0.93 to 1.1).    
Compared to individuals with ADPKD, significantly lower mean unadjusted 
hospitalizations, mean unadjusted hospital days and mean unadjusted outpatient visits 
were observed among those without ADPKD.  Mean annual unadjusted hospitalizations 
among individuals without ADPKD were 0.0085 (95 percent C.I.: 0.074 to 0.096).   
Mean annual unadjusted hospital days among individuals without ADPKD were 0.45 (95 
percent C.I.: 0.27 to 0.62).   Mean annual unadjusted outpatient visits among individuals 
without ADPKD were 9.7 (95 percent C.I.: 9.3 to 10.0).   No significant difference in the 
mean unadjusted nursing home confinements, nursing home length of stay or emergengy 
room visits were observed between person with ADPKD and those without ADPKD.  
Mean annual unadjusted nursing home confinements among individuals without ADPKD 
were 0.0031 (95 percent C.I.: 0.0013 to 0.0048) and the mean annual unadjusted nursing 
home length of stay was 0.071 (95 percent C.I.: 0.021 to 0.012).   Mean annual 
unadjusted emergency room visits among individuals without ADPKD were 0.68 (95 
percent C.I.: 0.61 to 0.76).    
All-cause health care resource utilization by age, gender and ADPKD 





Unadjusted Annual Health Care Expenditures 
Table 10 provides mean unadjusted annual health care expenditures for 
individuals with ADPKD and those without ADPKD.  Mean annual unadjusted inpatient 
expenditures among individuals with ADPKD were $6,646 (95 percent C.I.: $5,685 to 
$7,608).   Mean annual unadjusted nursing home expenditures among individuals with 
ADPKD were $252 (95 percent C.I.: $131 to $373).   Among individuals with ADPKD, 
mean annual unadjusted outpatient expenditures were $12,625 (95 percent C.I.: $11,550 
to $13,701) and the mean annual unadjusted emergency room expenditures were $174 
(95 percent C.I.: $157 to $191).   Mean annual unadjusted medication expenditures 
among individuals with ADPKD were $3,537 (95 percent C.I.: $3,324 to $3,751).   Mean 
annual unadjusted total health care expenditures among individuals with ADPKD were 
$23,242 (95 percent C.I.: $21,590 to $24,895).    
Compared to individuals with ADPKD, significantly lower mean annual 
unadjusted hospital expenditures, nursing home expenditures, outpatient expenditures, 
and medication expenditures were observed among individuals without ADPKD.  Mean 
annual unadjusted inpatient expenditures among individuals without ADPKD were 
$1,484 (95 percent C.I.: $1,234 to $1,734).   Mean annual unadjusted nursing home 
expenditures among individuals without ADPKD were $41 (95 percent C.I.: $13 to $69).   
Among individuals without ADPKD, mean annual unadjusted outpatient expenditures 
were $3,225 (95 percent C.I.: $2,797 to $3,653) and mean annual unadjusted medication 
expenditures were $1,380 (95 percent C.I.: $1,234 to $1,525).   Significant difference was 





Table 9. Unadjusted Annual Health Care Resource Utilization among Persons with ADPKD and those without ADPKD 
 ____________________________________________________________________________________________________________ 
 With ADPKD  Without ADPKD  
 (n=3,844) (n = 3,844) 
 _____________________  _______________________  
  Mean Mean 
Health Care Resource Category (95% CI) (95% CI) 
 ____________________________________________________________________________________________________________ 
Hospitalizations 0.24 0.085  
  (0.21 to 0.26) (0.074 to 0.096) 
 
Hospital days 2.0 0.45  
  (1.6 to 2.5) (0.27 to 0.62)  
 
Nursing home confinements 0.011 0.0031 
  (0.0077 to 0.015) (0.0013 to 0.0048) 
 
Nursing home length of stay 0.33 0.071 
  (0.18 to 0.49) (0.021 to 0.12)  
 
Outpatient visits 21.1 9.7 
  (20.3 to 21.9) (9.3 to 10.0) 
 
Emergency room visits 1.0 0.68  








Table 10. Unadjusted Annual Health Care Expenditures in Dollars among Persons with ADPKD and those without ADPKD 
 ____________________________________________________________________________________________________________ 
 With ADPKD  Without ADPKD  
 (n=3,844) (n = 3,844) 
  ______________________ _____________________ 
  Mean Mean 
Health Care Expenditure Category (95% CI) (95% CI) 
 ____________________________________________________________________________________________________________ 
Inpatient expenditures 6,646 1,484  
  (5,685 to 7,608) (1,234 to 1,734) 
 
Nursing home expenditures 252 41  
  (131 to 373) (13 to 69)  
 
Outpatient expenditures 12,625 3,225 
  (11,550 to 13,701) (2,797 to 3,653)  
 
Emergency room expenditures 174 100 
  (157 to 191) (89 to 111)  
 
Medication expenditures 3,537 1,380 
  (3,324 to 3,751) (1,234 to 1,525) 
 
Total health care expenditures 23,242 6,230  








with ADPKD and those without ADPKD, such that expenditures among individuals with 
ADPKD  were thrice as high $23,242 (95 percent C.I.: $21,590 to $24,895) compared to 
individuals without ADPKD $6,230 (95 percent C.I.: $5,668 to $6,791).    
All-cause health care resource utilization by age, gender and ADPKD 
complications are reported in Tables B1 to B8 under Appendix B. 
Incremental Annual Health Care Resource Utilization Associated with ADPKD  
Data distributional characteristics were examined and sequential assessment of potential 
regression techniques was conducted to select an appropriate model, for analysis of 
incremental resource utilization associated with ADPKD.  The models were examined in 
sequence beginning with ordinary least squares regression on the untransformed  
dependent variables, followed by ordinary least squares regression on the log transformed 
dependent variables, generalized linear models and zero-inflated generalized linear 
models.  Residuals of ordinary least squares regression models with untransformed and 
models with log transformed utilization and expenditure variables, showed violation of 
assumptions of normality and constant variance.  P-values lower than 0.05 for each 
Kolmogorov-Smirnov test showed that residuals for each ordinary least squares 
regression model were not normally distributed (D'Agostino and Stephens 1986).  Results 
of each Glejser test showed p-values lower than 0.05, confirming that residuals were 
significantly associated with independent variables (Glejser 1969).  Therefore, 
generalized linear models were developed and tested for model fit.   
Medical resource utilization and expenditure variables in this study had a high 





evidenced by p-values less than 0.05 for Vuong tests, suggested a need for a zero-inflated 
generalized linear model.(Long and Freese 2006; Vuong 1989)  Significant likelihood 
ratio tests, shown by p-values less than 0.05 indicated that for each dependent variable, 
zero-inflated negative binomial models were more suitable than zero-inflated Poisson 
models.(Long and Freese 2006; Vuong 1989; Cameron and Trivedi 1986)    
Results from multivariate zero-inflated negative binomial regression models for 
each health care resource utilization type are reported in Table 11.   For nursing home 
confinements, results from regression models were not available since the number of 
nursing home confinements were so low that models did not converge.  ADPKD was 
associated with more outpatient visits as reflected in a mean of 6.9 (0.28), p<0.05 
incremental outpatient visits.  Although ADPKD was associated with incrementally more 
hospitalizations, 0.087 (0.011), p<0.05, the impact of ADPKD on hospital resource 
utilization may be better reflected in the mean incremental hospital days, 0.68 (0.090), 
p<0.05.  Emergency room visits were also incrementally greater among persons with 
ADPKD, 0.29 (0.055), p<0.05. 
Incremental Annual Health Care Expenditures Associated with ADPKD  
Individual regression models were developed to estimate incremental health care 
expenditures associated with autosomal dominant ADPKD.  A binary predictor variable 
for ADPKD was included in each model and covariates in each model included age, 
gender, co-morbidity index score, cardiovascular disease, diabetes and geographical 





Table 11. Annual Incremental Health Care Resource Utilization Associated with ADPKD (n=7,688)a 
 __________________________________________________________________________________________________________________________  
     Comorbidity Cardiovascular 
  ADPKD Age Gender Index Disease Diabetes Midwest West South 
  _________  _________   ________   __________  _________   __________   _________   _________  _________  
Resource Marginal Marginal  Marginal Marginal Marginal Marginal Marginal Marginal Marginal 
Utilization Effectb Effectc Effectb Effectc Effectb Effectb Effectb Effectb Effectb 
Category (SE)  (SE)  (SE) (SE)  (SE)   (SE) (SE) (SE) (SE) 
 __________________________________________________________________________________________________________________________  
Hospitalizations  0.087** -0.0017** -0.023 0.063** 0.076* -0.0047 0.0071 -0.019 -0.019
  (0.011) (0.00042) (0.012) (0.0082) (0.034) (0.018) (0.017) (0.019) (0.017) 
 
Hospital days 0.68** -0.012** 0.15 0.41** 0.42** -0.34* 0.0022 -0.20 -0.18 
  (0.090) (0.0028) (0.081) (0.050) (0.11) (0.11) (0.13) (0.15) (0.12) 
 
Nursing home NA NA NA NA NA NA NA NA NA 
confinements     
  
Nursing home 0.028 0.0024* -0.019 0.0084* 0.021 -0.0061 0.0082 -0.0094 -0.018l 
days (0.018) (0.00091) (0.012) (0.0042) (0.014) (0.012) (0.017) (0.019) (0.019) 
 
Outpatient 6.9** 0.10** -3.8** 2.9** 1.0* -0.91* -2.2** -1.3* -1.9** 
visits (0.28) (0.010) (0.28) (0.11) (0.11) (0.42) (0.49) (0.52) (0.46) 
 
Emergency room 0.29** -0.0045* -0.21** 0.045 0.22* 0.15 0.038 0.16 -0.026 
visits (0.055) (0.0022) (0.054) (0.023) (0.088) (0.087) (0.096) (0.10) (0.087) 
 ________________________________________________________________________________________________________________  
aResults from zero-inflated negative binomial regression models.  The dependent variables for models are listed in the columns and the independent variables in the rows.  The marginal 
effects are estimated at the starting value for each independent variable fixed at the observed mean value for the entire sample (persons with or without ADPKD), that is, proportion with 
PKD 50%, age at 49.14 years, proportion of males at 0.46, Charlson Comorbidity Index at 1.14, proportion of cardiovascular disease 19.4%, proportion of diabetes 12.04%, proportion of 
Midwest 27.3%, proportion of West 17.3% and proportion of South 44.9%. 
b Marginal effects for dichotomous variables are change in the expected value of the dependent variable for the discrete change from 0 to 1 of the independent variable, that is, from no 
ADPKD to ADPKD and woman to man. 
c Marginal effects for continuous variables are change in the expected value of the dependent variable for a unit change in the independent variable, given a specific starting value for the 
independent variable. 
*p <0.05, **p<0.001 based on z-test.   







Smirnov test showed that residuals for each ordinary least squares regression model were 
not normally distributed (D'Agostino and Stephens 1986).  Results of each Glejser test 
showed p-values lower than 0.05, confirming that residuals were significantly associated 
with independent variables (Glejser 1969).  Medical expenditure variables in this study 
had a high number of observations with zeros.  Overdispersion of each health care 
expenditure variable evidenced by  p-values less than 0.05 for Vuong tests, suggested a  
need for a zero-inflated generalized linear model.(Long and Freese 2006; Vuong 1989)  
Significant likelihood ratio tests, shown by p-values less than 0.05 indicated that for each 
dependent variable, zero-inflated negative binomial models were more suitable than zero-
inflated Poisson models.(Long and Freese 2006; Vuong 1989; Cameron and Trivedi 
1986)   Results from multivariate zero-inflated negative binomial regression models for 
each health care expenditure type are reported in Table 12.   The mean incremental 
expenditures for outpatient expenditures associated with ADPKD, $4,507 (181), p<0.05, 
accounted for the largest incremental expenditure.  Hospital expenditures had the second 
largest incremental effect associated with ADPKD, $2,385 ($241), p<0.05.  As shown in 
Table 12, significant incremental expenditures associated with ADPKD were also found 
for medication expenditures, $1,456 ($71), p<0.05 and emergency room expenditures, 
$62 ($7), p<0.05.  The mean estimate of incremental total health care expenditures 





Table 12. Annual Incremental Health Care Expenditures in Dollars Associated with ADPKD (n=7,688)a 
 _________________________________________________________________________________________________________________________  
     Comorbidity Cardiovascular 
  ADPKD Age Gender Index Disease Diabetes Midwest West South 
  _________  _________   ________   __________  _________   __________   _________   _________  _________  
Health Care Marginal Marginal  Marginal Marginal Marginal Marginal Marginal Marginal Marginal 
Expenditure Effectb Effectc Effectb Effectc Effectb Effectb Effectb Effectb Effectb 
Category (SE)  (SE)  (SE) (SE)  (SE)  (SE) (SE) (SE) (SE) 
 _________________________________________________________________________________________________________________________  
Hospital 2,385** -25* 1 991** 1,167** -250 3 -803 -544 
expenditures (241) (8) (215) (76) (279) (285) (374) (420) (356) 
 
Nursing home  22 1* -5 5 18 4 4 -6 -7 
expenditures  (14) (0.61) (7) (2) (11) (8) (12) (13) (13) 
 
Outpatient 4,507** 26** -1,100** 1,923** 428 -1,135** 140 515 1,028** 
expenditures (181) (7) (168) (74) (260) (263) (296) (320) (279) 
 
Emergency room 62** -1** -36** 11** 53** 9 35* 37* 19  
expenditures (7) (0.31) (7) (3) (11) (12) (13) (14) (12) 
 
Medication 1,456** 30** -97 629** 47 224* 170 97 292* 
expenditures (71) (2) (68) (29) (102) (105) (120) (131) (113) 
 
Total health care 7,917** 48** -1,237** 3,562** 1,604** -1,228* 267 -449 419 
expenditures  (431) (11) (297) (131) (455) (465) (525) (568) (494) 
 _________________________________________________________________________________________________________________________  
aResults from  zero-inflated negative binomial regression models.  The dependent variables for models are listed in the columns and the independent variables in the rows.  The marginal 
effects are estimated at the starting value for each independent variable fixed at the observed mean value for the entire sample (persons with or without autosomal dominant ADPKD), that 
is, proportion with ADPKD 50%, age at 49.14 years, proportion of males at 0.46, Charlson Comorbidity Index at 1.14, proportion of cardiovascular disease 19.4%, proportion of diabetes 
12.04%, proportion of Midwest 27.3%, proportion of West 17.3% and proportion of South 44.9%. 
b Marginal effects for dichotomous variables are change in the expected value of the dependent variable for the discrete change from 0 to 1 of the independent variable, that is, from no 
ADPKD to ADPKD and woman to man. 
c Marginal effects for continuous variables are change in the expected value of the dependent variable for a unit change in the independent variable, given a specific starting value for the 
independent variable. 
*p <0.05, **p<0.001 based on z-test.   






Sub-Group Analysis by whether Diagnosed with End-Stage Renal Disease 
Unadjusted Annual Health Care Resource Utilization  
by whether Diagnosed with End-Stage Renal Disease 
Among 3,844 persons with ADPKD, 644 had a diagnosis of end-stage renal 
disease and 3,200 persons with ADPKD had not been diagnosed with end-stage renal 
disease.  Unadjusted resource utilization among persons with ADPKD by whether 
diagnosed with end-stage renal disease is reported in Table 13.   
Mean annual unadjusted hospitalizations were more than three times higher among 
ADPKD patients with end-stage renal disease 0.56 (95 percent C.I.: 0.49 to 0.64).   as 
compared to ADPKD patients without end-stage renal disease 0.17 (95 percent C.I.: 0.15 
to 0.19), p <0.05.  Individuals with ADPKD and end-stage renal disease had more than 
four times greater mean annual unadjusted hospital days 5.7 (95 percent C.I.: 3.7 to 7.8) 
as compared to ADPKD patients without end-stage renal disease 1.3 (95 percent C.I.: 
0.94 to 1.7), p <0.05.  Mean annual unadjusted outpatient visits were approximately three 
times as great among individuals with ADPKD and end-stage renal disease 44.6 (95 
percent C.I.: 41.6 to 47.7) as compared to those with ADPKD but without end-stage renal 
disease 16.3 (95 percent C.I.: 15.7 to 16.9), p <0.05.   
Unadjusted Annual Health Care Expenditures 
by whether Diagnosed with End-Stage Renal Disease 
Table 14 compares mean unadjusted annual health care expenditures for 
individuals with ADPKD and end-stage renal disease and those with ADPKD but without 





Table 13. Unadjusted Annual Health Care Resource Utilization among Persons with 
ADPKD by whether Diagnosed with End-Stage Renal Disease (ESRD)a 
 ______________________________________________________________________  
   No ESRD ESRD 
   (n=3,200) (n=644) 
  ____________________   ____________________  
   Mean Mean 
Utilization Category (95% CI) (95% CI) 
 ______________________________________________________________________  
Hospitalizations 0.17 0.56  
   (0.15 to 0.19) (0.49 to 0.64) 
 
Hospital days 1.3 5.7 
   (0.94 to 1.7) (3.7 to 7.8) 
  
Nursing home confinements 0.0094 0.023 
   (0.0054 to 0.013) (0.010 to 0.036) 
  
Nursing home days 0.30 0.50 
   (0.13 to 0.47) (0.14 to 0.85) 
  
Outpatient visits 16.3 44.6 
   (15.7 to 16.9) (41.6 to 47.7) 
  
Emergency room visits 1.1 1.0 
   (0.96 to 1.2) (0.78 to 1.2) 
 ______________________________________________________________________  
a A diagnosis of ICD-9-CM code 585.6 during the study period from April 1, 2011 to 





Table 14. Unadjusted Annual Health Care Expenditures in Dollars among Persons with 
ADPKD by whether Diagnosed with End-Stage Renal Disease (ESRD)a 
 ______________________________________________________________________  
   No ESRD ESRD 
   (n=3,200) (n=644) 
  ____________________   ____________________  
   Mean Mean 
Expenditure Category (95% CI) (95% CI) 
 ______________________________________________________________________  
Inpatient expenditures 3,974 19,927  
   (3,280 to 4,668) (15,471 to 24,384) 
 
Nursing home expenditures 189 566 
   (90 to 288) (33 to 1,100) 
 
Outpatient expenditures 5,352 48,767  
   (4,977 to 5,727) (43,431 to 54,103)  
  
Emergency room expenditures 176 194 
   (157 to 196) (153 to 234) 
 
Medication expenditures 2,439 8,995 
   (2,234 to 2,644) (8,381 to 9,610) 
 
Total health care expenditures 12,131 78,451  
   (11,174 to 13,089) (71,168 to 85,733)  
 ______________________________________________________________________  
a A diagnosis of ICD-9-CM code 585.6 during the study period from April 1, 2011 to 





higher for individuals with ADPKD and end-stage renal disease $19,927 (95 percent C.I.: 
$15,471 to $24,384) as compared to individuals with ADPKD but without end-stage renal 
disease $3,974 (95 percent C.I.: $3,280 to $4,668), p <0.05.  Mean annual unadjusted 
expenditures from nursing homes were three-fold higher for the patients with ADPKD 
and end-stage renal disease $566 (95 percent C.I.: $33 to $1,100) than for those ADPKD 
patients without end-stage renal disease $189 (95 percent C.I.: $90 to $288), p <0.05.The 
unadjusted mean annual outpatient expenditures were nine times higher among 
individuals with ADPKD and end-stage renal disease $48,767 (95 percent C.I.: $43,431 
to $54,103) than for ADPKD patients without end-stage renal disease $5,352 (95 percent 
C.I.: $4,997 to $5,727), p <0.05.  The mean annual unadjusted medication expenditure for 
individuals with ADPKD and end-stage renal disease $8,995 (95 percent C.I.: $8,381 to 
$9,610) were approximately four times higher when compared to individuals with 
ADPKD but without end-stage renal disease $2,439 (95 percent C.I.: $2,234 to $2,644), 
p<0.05.  Mean unadjusted expenditures among individuals with ADPKD and end-stage 
renal disease $78,451 (95 percent C.I.: $71,168 to $85,733) were 6.5 times higher 
compared to ADPKD patients without end-stage renal disease $12,131 (95 percent C.I.: 
$11,174 to $13,089), p <0.05. 
Incremental Annual Health Care Resource Utilization  
by whether Diagnosed with End-Stage Renal Disease 
Table 15 shows incremental health care resource utilization associated with 
ADPKD, based on results of zero-inflated negative binomial models by whether 
diagnosed with end-stage renal disease.  Significant incremental, mean (standard error) 





associated with ADPKD in the sub-group with end-stage renal disease.  There were also 
significant incremental hospitalizations, 0.065 (0.028), p<0.05 associated with ADPKD 
in the sub-group without end-stage renal disease and significant incremental hospital 
days, 0.50 (0.091), p<0.05 associated with ADPKD in the sub-group without end-stage 
renal disease.   
For the sub-group with end-stage renal disease, incremental outpatient visits were 
24.0 (1.2), p<0.05, which were several times higher than the incremental outpatient visits 
associated with ADPKD for the subgroup without end-stage renal disease, 4.4 (0.41), 
p<0.05.  In contrast, the sub-group analysis revealed that there were not significant 
incremental emergency room visits associated with ADPKD in the sub-group with end-
stage renal disease, but that the sub-group without end-stage renal disease did have 
significant incremental emergency room visits associated with ADPKD, 0.32 (0.058), 
p<0.05.  
Incremental Annual Health Care Expenditures 
by whether Diagnosed with End-Stage Renal Disease 
Results from sub-group analyses of incremental expenditures associated with 
ADPKD are also reported in Table 16.  The ADPKD sub-group with end-stage renal 
disease had mean incremental total expenditures associated with ADPKD $42,547 
($2,102), p<0.05, that were much higher than those for the sub-group with ADPKD but 
without end-stage renal disease $3,053 ($374), p<0.05.     
Similar relationships were seen in comparison across the sub-group with end-
stage renal disease and the sub-group without end-stage renal disease, for incremental 





expenditures $26,539 ($1,373) p<0.05 versus $1,247 ($119), p<0.05; and medication 
expenditures $5,933 ($342), p<0.05 versus $824 ($61), p<0.05 respectively.  However, 
incremental emergency room expenditures associated with ADPKD were of similar 
magnitude for the sub-group with end-stage renal disease $67 ($22), p<0.05 and the sub-





Table 15. Adjusted Annual Incremental Health Care Resource Utilization Associated with ADPKD  
by whether Diagnosed with End-Stage Renal Diseasea 
 _________________________________________________________________________________________________________________________  
     Comorbidity Cardiovascular 
  ADPKD Age Gender Index Disease Diabetes Midwest West South 
  _________  _________   ________   __________  _________   __________   _________   _________  _________  
Resource Marginal Marginal  Marginal Marginal Marginal Marginal Marginal Marginal Marginal 
Utilization Effectb Effectc Effectb Effectc Effectb Effectb Effectb Effectb Effectb 
Category (SE)  (SE)  (SE) (SE)  (SE)  (SE) (SE) (SE) (SE) 
 _________________________________________________________________________________________________________________________  
Hospitalizations  
 ESRDd 0.35** -0.0043 -0.067 0.093** 0.097 -0.034 -0.018 -0.052 -0.13 
  (0.052) (0.0023) (0.048) (0.019) (0.063) (0.061) (0.078) (0.092) (0.075) 
 
 No-ESRDe 0.065* -0.0018** -0.0073 0.048* 0.070 0.0039 0.022 -0.0092 -0.0098 
  (0.028) (0.00050) (0.030) (0.019) (0.087) (0.026) (0.031) (0.020) (0.018) 
 
Hospital days 
 ESRDd 2.5** -0.044* -0.28 0.71** 0.57 -0.99* -1.0 -1.7* -1.4* 
  (0.42) (0.017) (0.33) (0.15) (0.42) (0.47) (0.63) (0.70) (0.62) 
 
 No-ESRDe 0.50** -0.011** 0.23* 0.39** 0.33* -0.18 0.22 -0.0056 -0.0079 
  (0.091) (0.0028) (0.090) (0.059) (0.13) (0.12) (0.14) (0.15) (0.12) 
Nursing home    
confinements  
 ESRDd NA NA NA NA NA NA NA NA NA 
   
 
 No-ESRDe NA NA NA NA NA NA NA NA NA 
  
 
Nursing home days    
 ESRDd NA NA NA NA NA NA NA NA NA
    
 
 No-ESRDe 0.018 0.0015 -0.022 0.0033 0.013 -0.013 0.0042 -0.0098 -0.015 







Table 15. Continued 
 _________________________________________________________________________________________________________________________  
     Comorbidity Cardiovascular 
  ADPKD Age Gender Index Disease Diabetes Midwest West South 
  _________  _________   ________   __________  _________   __________   _________   _________  _________  
Resource Marginal Marginal  Marginal Marginal Marginal Marginal Marginal Marginal Marginal 
Utilization Effectb Effectc Effectb Effectc Effectb Effectb Effectb Effectb Effectb 
Category (SE)  (SE)  (SE) (SE)  (SE)  (SE) (SE) (SE) (SE) 
 _________________________________________________________________________________________________________________________  
Outpatient visits 
 ESRDd 24.0** 0.010 -3.6** 3.0** 0.63 -0.43 -2.3 -0.97 -2.1 
  (1.2) (0.05) (1.0) (0.34) (1.3) (1.4) (1.9) (2.1) (1.8) 
 
 No-ESRDe 4.4** 0.091** -3.9** 2.4** 0.57 -0.85* -2.7** -1.6* -2.3** 
  (0.41) (0.012) (0.26) (0.11) (0.41) (0.41) (0.45) (0.49) (0.42) 
 
Emergency room  
visits   
 ESRDd 0.12 -0.022 0.12 -0.023 0.30 0.083 0.25 0.51 0.22 
  (17.2) (1.4) (7.8) (3.9) (14.0) (9.9) (10.6) (25.5) (5.3) 
 
 No-ESRDe 0.32** -0.0031 -0.28** 0.061* 0.19 0.14 -0.018 0.094 -0.082 
  (0.058) (0.0024) (0.059) (0.027) (0.10) (0.098) (0.10) (0.10) (0.094) 
 _________________________________________________________________________________________________________________________  
aAnalysis based on zero-inflated negative binomial regression models.  The dependent variables for models are listed in the columns and the independent variables in the rows.  The 
marginal effects are estimated at the starting value for each independent variable fixed at the observed mean value for the entire sample (persons with or without autosomal dominant 
ADPKD), that is, proportion with ADPKD 50%, age at 49.14 years, proportion of males at 0.46, Charlson Comorbidity Index at 1.14, proportion of cardiovascular disease 19.4%, 
proportion of diabetes 12.04%, proportion of Midwest 27.3%, proportion of West 17.3% and proportion of South 44.9%. 
b Marginal effects for dichotomous variables are change in the expected value of the dependent variable for the discrete change from 0 to 1 of the independent variable, that is, from no 
ADPKD to ADPKD and woman to man. 
c Marginal effects for continuous variables are change in the expected value of the dependent variable for a unit change in the independent variable, given a specific starting value for the 
independent variable. 
d 644 individuals with ADPKD with end-stage renal disease linked with 644 comparison observations 
e 3,200 individuals with ADPKD without end-stage renal disease linked with 3,200 comparison observations 
*p <0.05, **p<0.001 based on z-test.   







Table 16. Adjusted Annual Incremental Health Care Expenditures in Dollars Associated with ADPKD  
by whether Diagnosed with End-Stage Renal Diseasea   
 _________________________________________________________________________________________________________________________  
     Comorbidity Cardiovascular 
  ADPKD Age Gender Index Disease Diabetes Midwest West South 
  ________   _________   _________   _________   __________   __________  _________   ________   _________  
Health Care Marginal Marginal  Marginal Marginal Marginal Marginal Marginal Marginal Marginal 
Expenditure Effectb Effectc Effectb Effectc Effectb Effectb Effectb Effectb Effectb 
Category (SE)  (SE)  (SE) (SE)  (SE)  (SE) (SE) (SE) (SE) 
 _________________________________________________________________________________________________________________________  
Hospital 
expenditures 
 ESRDd 9,430** -148* -149 1,765** 1,868 -745 -3,638* -5,873* -4,992* 
  (1,179) (49) (977) (317) (1,221) (1,207) (1,826) (2,108) (1,748) 
 
 No-ESRDe 1,365** -17* -42 727** 880* -8 527 -11 23 
  (207) (7) (195) (69) (257) (269) (335) (371) (318) 
Nursing home   
expenditures 
 ESRDd 88 -1 67 19 76 41 30 130 37 
  (58) (2) (48) (13) (44) (37) (49) (105) (48) 
 
 No-ESRDe 9 0.84* -10 2 8 -5 4 -3 -7 
  (6) (0.38) (6) (1) (5) (5) (6) (6) (7) 
Outpatient  
expenditures    
 ESRDd 26,539** -51 -1,873* 2,582** -67 -998 -538 830 874 
  (1,373) (47) (913) (336) (1,236) (1,270) (1,741) (1,891) (1,655) 
 
 No-ESRDe 1,247** 11* -1,066** 1,103** 35 -656* -434* 105 301 
  (119) (5) (122) (52) (187) (194) (209) (226) (197) 
Emergency room  
expenditures   
 ESRDd  67* -2* -17 3 44 25 54 75 58 
 (22) (1) (20) (6) (26) (28) (41) (43) (38) 
   
 No-ESRDe  63** -1** -41** 14** 56** 4 34* 34* 14 






Table 16. Continued 
 _________________________________________________________________________________________________________________________  
     Comorbidity Cardiovascular 
  ADPKD Age Gender Index Disease Diabetes Midwest West South 
  ________   _________   _________   _________   __________   __________  _________   ________   _________  
Health Care Marginal Marginal  Marginal Marginal Marginal Marginal Marginal Marginal Marginal 
Expenditure Effectb Effectc Effectb Effectc Effectb Effectb Effectb Effectb Effectb 
Category (SE)  (SE)  (SE) (SE)  (SE)  (SE) (SE) (SE) (SE) 
 _________________________________________________________________________________________________________________________  
Medication 
expenditures  
 ESRDd  5,933** 20 115 537** -191 742* -141 -609 84 
  (342) (13) (266) (86) (339) (364) (502) (553) (478) 
 
 No-ESRDe  824** 23** -143* 568** 7 166 90 102 228* 
  (61) (2) (61) (28) (97) (98) (107) (117) (100) 
 
Total health care  
expenditures   
 ESRDd  42,547** -78 -942 4,908** 2,409 -1,816 -5,172 -5,294 -5,326* 
  (2,102) (74) (1,478) (522) (1,907) (2,063) (2,789) (3,045) (2,644) 
 
 No-ESRDe  3,053** 20* -1,320** 2,475** 1,415** -602 151 -7 540 
  (374) (8) (238) (108) (375) (385) (415) (448) (390) 
 _________________________________________________________________________________________________________________________  
aAnalysis based on zero-inflated negative binomial regression models.  The dependent variables for models are listed in the columns and the independent variables in the rows.  The marginal 
effects are estimated at the starting value for each independent variable fixed at the observed mean value for the entire sample (persons with or without autosomal dominant ADPKD), that is, 
proportion with ADPKD 50%, age at 49.14 years, proportion of males at 0.46, Charlson Comorbidity Index at 1.14, proportion of cardiovascular disease 19.4%, proportion of diabetes 
12.04%, proportion of Midwest 27.3%, proportion of West 17.3% and proportion of South 44.9%. 
b Marginal effects for dichotomous variables are change in the expected value of the dependent variable for the discrete change from 0 to 1 of the independent variable, that is, from no 
ADPKD to ADPKD and woman to man. 
c Marginal effects for continuous variables are change in the expected value of the dependent variable for a unit change in the independent variable, given a specific starting value for the 
independent variable. 
d 644 individuals with ADPKD with end-stage renal disease linked with 644 comparison observations 
e 3,200 individuals with ADPKD without end-stage renal disease linked with 3,200 comparison observations 
*p <0.05, **p<0.001 based on z-test.   
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SUMMARY AND CONCLUSIONS 
Background 
Polycystic kidney disease is the most common hereditary kidney disorder (Pirson 
and Chauveau 1999; Wilson 2004).  It is characterized by growth and development of 
multiple fluid filled sacs known as cysts that cause gradual kidney damage and 
significant morbidity (Grantham 2008; Pirson and Chauveau 1999; Torres, Harris, and 
Pirson 2007; Wilson 2004).  PKD is characterized by gradual kidney enlargement and 
other sequelae including colonic diverticulitis, polycystic liver disease, intracranial 
aneurysms, and cysts in other tissues such as seminal vesicles, arachnoid membranes and 
the pancreas (Alehan, Gurakan, and Agildere 2002; Danaci et al. 1998; Grantham 2008; 
Nicolau et al. 2000; Pirson, Chauveau, and Torres 2002; Schievink et al. 1995; Torres, 
Harris, and Pirson 2007; Wijdicks, Torres, and Schievink 2000).  As cysts develop and 
grow in size, they impinge upon kidney parenchyma, ultimately rendering the kidneys 
dysfunctional, and the condition eventually progresses to end-stage renal disease 
(Grantham 2008; Torres, Harris, and Pirson 2007; Torres and Grantham 2007; Wilson 
2004). 
Autosomal dominant polycystic kidney disease (ADPKD) is the most common 





 approximately 500,000 Americans (Grantham 2008; Pirson and Chauveau 1999; Torres, 
Harris, and Pirson 2007).  ADPKD may be asymptomatic for several decades but as cysts 
increase in size and number, symptoms and serious sequelae develop.  Autosomal 
recessive PKD is much rarer than ADPKD and it occurs in only about 1 in 20,000 live 
births (Grantham 2008; Pirson and Chauveau 1999).   Symptom presentation is more 
rapid and occurs at an earlier age for persons with autosomal recessive PKD than for 
persons with ADPKD, so that ADPKD is more likely to be a long term chronic condition 
(Dell and Avner 2001; Pirson and Chauveau 1999; Wilson 2004).   
This study provides a current description of the epidemiology of ADPKD by 
estimating its one year prevalence.  There is limited evidence describing economic 
burden of ADPKD.  Only one study was found that estimated all-cause health care costs 
for persons with ADPKD (Lentine et al. 2010)  and the reported mean annual unadjusted 
all-cause total health care expenditures ranged from $26,521 at baseline to $140,139 at 
the advanced kidney disease level (Lentine et al. 2010).  No study was found that 
assessed incremental health care resource utilization or incremental health care 
expenditures associated with ADPKD.  Additional evidence regarding the burden of 
ADPKD may offer valuable input in understanding the societal impact of the disease. 
Objectives 
The specific objectives for this study were to  
1. determine prevalence of ADPKD  in a private-pay population, 
2. determine all-cause health care resource utilization and expenditures among 





3. determine incremental health care resource utilization associated with ADPKD by 
categories including hospitalizations, hospital days, nursing home visits, nursing 
home length of stay, emergency room encounters and  outpatient encounters, and  
4. determine incremental health care expenditures associated with ADPKD by 
categories including total expenditures, hospital stay, nursing home stay, 
emergency room encounters, outpatient services and medication. 
Methods 
Health insurance claims data from a large administrative database between April 
1, 2011 and March 31, 2012 were used to conduct an observational database analysis.  
The database included medical and pharmacy claims for 13 million privately-insured 
lives covering all census regions of the United States.  To account for pricing variation 
across providers or geographic regions, standard prices in the database reflected allowed 
payments from a single source with a consistent payment plan.  The study was approved 
by the Institutional Review Board of Purdue University. 
Sample 
Individuals 18 years of age or older and enrolled in a tracked health plan anytime 
during  the period from April 1, 2011 through March 31, 2012, were eligible for inclusion 
in the sample for determination of ADPKD prevalence.  No exclusion criteria were 





Persons age 18 years or older, enrolled in a tracked health plan during the twelve-
month period from April 1, 2011 through March 31, 2012, and having a diagnosis for 
“polycystic kidney, autosomal dominant” (753.13) or for “polycystic kidney, unspecified 
type (753.12) were selected for inclusion in the sample for determining all-cause health 
care resource utilization and expenditures as well as incremental health care resource 
utilization and expenditures associated with ADPKD.  Persons having ICD-9-CM 
diagnosis codes for “polycystic kidney, autosomal recessive” (753.14) or “cystic kidney 
disease” (753.1) were excluded from the ADPKD group because of their differing 
clinical presentation and prognosis.  Each individual in the ADPKD group was linked 
one-to-one on age and gender with an individual without ADPKD.  The comparison 
group without ADPKD consisted of individuals who satisfied all inclusion criteria for the 
ADPKD group but did not have a diagnosis for ADPKD.  Exclusion criteria for the non-
ADPKD group were  a diagnosis for  autosomal recessive PKD,  cystic kidney disease, 
chronic kidney disease ranging from stage 3 to stage 6, nephrotic syndrome, diabetic 
kidney disease, or kidney stones associated with cystic kidney disease.  Renal diseases 
were excluded from the comparison group so as to avoid potential confounding from 
associated resource utilization and expenditures from those renal diseases.  Demographic 
variables including year of birth, gender, and geographic region were extracted from 
eligibility and claims files.  A modified Charlson Comorbidity Index developed by 
Romano et al. was constructed for the sample,  in which renal diseases were excluded in 






Data were analyzed using SAS for Unix Version 9.2 and STATA for Unix version 
12.  Frequency distributions were developed to describe the sample and Chi-square tests 
were used to assess statistical differences between persons with ADPKD and those 
without ADPKD on, demographic variables and clinical variables.  To estimate one-year 
prevalence of ADPKD, the number of individuals 18 years or older with ICD-9 diagnosis 
codes for “polycystic kidney, autosomal dominant” (753.13) or for “polycystic kidney, 
unspecified type” (753.12), and enrolled anytime during the period from April 1, 2011 
through March 31, 2012, were identified and divided by the total population of covered 
individuals 18 years or older, during the same one year period.  A 95 percent confidence 
interval of the estimated prevalence was constructed.  Health care resource utilization by 
specific categories was calculated for each individual and health care expenditures by 
specific categories were computed by adding standard prices from insurance claims.  
Unadjusted means and 95 percent confidence intervals for utilization and expenditure in 
each category were also computed, and Wilcoxon Mann Whitney tests were used to 
detect differences between the groups.   
Individual regression models were developed to estimate independent association 
between ADPKD and utilization of health services such that individual models were 
developed for hospitalizations, hospital days, nursing home confinements, nursing home 
days, outpatient visits and emergency room visits.  A binary predictor variable for 
ADPKD was included in each model and covariates in each model included age, gender, 





adjust for these risk factors.  Similar regression models for health care expenditures were 
developed, with the predictor variable and covariates described above, with individual 
models for total expenditures, hospital expenditures, nursing home expenditures, 
outpatient expenditures, emergency room expenditures, and medication expenditures.  
Sub-group analysis examined incremental resource utilization and expenditures 
associated with ADPKD by whether diagnosed with end-stage renal disease.  ADPKD 
cases with a diagnosis of end-stage renal disease (ICD-9-CM code 585.6) and their linked 
comparison individuals were one sub-group and cases without end-stage renal disease 
and their linked comparison individuals formed the other sub-group.  Individual 
regression models, as described for the overall analysis, were developed to estimate 
incremental resource utilization and expenditures by category for each sub-group 
adjusting for risk factors. 
Results and Discussion 
Demographic Characteristics of Prevalence Sample  
In the prevalence sample, 81.9 percent of individuals with ADPKD were 35 years 
of age older.  The proportion of females with ADPKD (53%) was higher than for males 
with ADPKD (47%).     
Prevalence of ADPKD 
From 10,500,664 persons at least 18 years old and enrolled during the period from 





CM diagnosis code for “polycystic kidney, autosomal dominant” (753.13) or for 
“polycystic kidney, unspecified type (753.12).  The number of ADPKD patients (5,878) 
was divided by the number of all covered individuals (10,500,664) to calculate the one-
year prevalence of the disease.  The prevalence of ADPKD was one in 1,786 persons or 
560 cases per million population.  The 95 percent confidence interval for estimated 
prevalence was between 1,833 to 1,742 persons.   
The only prior estimate of prevalence of ADPKD in the United States was 
reported to be between one in 400 persons to one in 1,000 persons (Iglesias et al. 1983).  
The prevalence of ADPKD in the United States estimated in this study, one in 1,786 
persons, was lower than the ADPKD prevalence estimate reported by Iglesias and 
colleagues (one in 400 to one in 1,000).  Five other studies have estimated prevalence of 
ADPKD in populations outside the United States (Davies et al. 1991; Higashihara et al. 
1998; Simon et al. 1996; Yersin et al. 1997; Dalgaard 1957).  The prevalence of ADPKD 
in the current study, one in 1,786 persons, was lower than the estimated prevalence in 
Seychelles, one in 544 (Yersin et al. 1997), in Copenhagen, one in 1,000 (Dalgaard 
1957), and in France, one in 1,111 (Simon et al. 1996).  However, the current prevalence 
estimate was higher than the estimated ADPKD prevalence in Wales, one in 2,459 
(Davies et al. 1991) and Japan, one in 4,033 (Higashihara et al. 1998). 
Some reasons for variation in prevalence estimates across studies may include 
differences between the samples used to calculate prevalence, differences in diagnostic 
techniques available during each study period or differing case identifying approaches 
used across studies.  The study by Iglesias et al. estimated ADPKD prevalence during a 





autopsy records of all residents of Olmsted County in Minnesota (Iglesias et al. 1983).  
Yersin et al. estimated prevalence in Seychelles by requesting all doctors employed in the 
national health system to refer all presumed or confirmed cases and by examining the 
family members of all confirmed cases (Yersin et al. 1997).  Dalgaard estimated 
prevalence from annual reports and autopsy records of maternity clinics of one hospital in 
Copenhagen, between 1911 to 1953 (Dalgaard 1957).  The prevalence estimate from 
France was based on a survey of individuals and their families from one region in France 
(Simon et al. 1996).  The study by Davies et al. estimated prevalence in Wales using a 
renal patient data repository from four nephrology clinics (Davies et al. 1991).   
In contrast, the current study estimated one-year prevalence using insurance 
claims records of privately-insured individuals across all census regions in the United 
States.  A diagnosis of ADPKD was identified by presence of ICD-9-CM diagnosis 
codes.  The prevalence of ADPKD obtained in this study may have been lower because 
administrative data was limited to privately insured patients only, autopsy records were 
not examined.  However, an estimate from a broader population such as the one reported 
in this current study is an improvement over the previously available U.S. prevalence 
estimate (Iglesias et al. 1983) which sampled the population of a single U.S. county. 
The findings on prevalence of ADPKD may help in understanding disease 
epidemiology relative to other diseases, and may inform decisions for allocation of 
resources by public institutions for research directed towards ADPKD.  Availability of 
updated epidemiological data regarding ADPKD may be useful for patient advocacy 
groups to provide current disease-related information to patients, payers and providers, 





All-Cause Resource Utilization and Expenditures 
Sample Characteristics 
Out of 10,500,664 persons at least 18 years old and enrolled during the 12-month 
period from April 1, 2011 through March 31, 2012, there were 4,020 individuals who had 
a diagnosis for ADPKD.  After excluding 115 individuals who either had a diagnosis of 
autosomal recessive ADPKD or unspecified cystic kidney disease, and 61 persons who 
had no medical claim information, a total of 3,844 individuals remained in the ADPKD 
group.  The individuals with an ADPKD diagnosis were linked one-to-one with 3,844 
individuals without ADPKD.  The final sample size for determining all-cause health care 
resource utilization and expenditures was 7,688.  The sample was 53 percent female, with 
a mean age ± standard deviation of 49.15 ± 13.67.  Approximately 55 percent were 
between 45 and 64 years old.  A significantly higher proportion of individuals in the 
ADPKD group had Charlson Comorbidity Index scores greater than zero (55.8% versus 
37.5%, p<0.05).  The cohort with ADPKD also had proportionally higher diagnosis of 
cardiovascular disease (25.6% versus 13.3%, p<0.05) and diabetes (14.1% versus 10.0%, 
p<0.05) than those without ADPKD.  Among individuals with ADPKD, 20.1 percent 
patients had at least one ADPKD complication.  Urinary tract infection was the most 
common ADPKD complication (15.6 %), followed by kidney stones (8.1%) and liver 






Unadjusted Annual Health Care Resource Utilization 
Mean annual unadjusted hospitalizations were three times higher among 
individuals with ADPKD (0.24) as compared to those without ADPKD (0.085), p<0.05.  
Individuals with ADPKD had four times greater mean annual unadjusted hospital days 
(2.0) as compared to individuals without ADPKD (0.45), p<0.05.  Mean annual 
unadjusted outpatient visits were more than twice as great among individuals with 
ADPKD (21.1) as compared to those without ADPKD (9.7), p<0.05.   
Findings from this study are consistent with findings from prior studies that 
reported higher resource utilization in persons with chronic kidney diseases compared to 
individuals without chronic kidney disease (Alexander et al. 2009; Baumeister et al. 
2010; Khan et al. 2002).  However, differences were observed between some types of all-
cause resource utilization among ADPKD patients compared to corresponding resource 
utilization among patients with chronic kidney disease in general.  The estimate of all-
cause mean hospitalizations among ADPKD patients found in this study, 0.24 (95 percent 
C.I.: 0.21 to 0.26), was higher than all-cause mean (± standard deviation) hospitalizations 
among patients with early stages of chronic kidney disease (stage 1 or stage 2), 0.19 ± 
0.01 but  lower than all-cause mean hospitalizations among persons with late-stage 
chronic kidney disease (stage 3 or stage 4), 0.42 ± 0.03, reported by Alexander et al. 
(Alexander et al. 2009).  When compared to results from a study by Khan and colleagues, 
the estimate of all-cause annual mean hospitalizations reported in the current study, 0.24 
(95 percent C.I.: 0.21 to 0.26), was lower than the 0.96 all-cause annual mean 





disease from an outpatient nephrology clinic (Khan et al. 2002).  The all-cause annual 
mean hospital days, 2.0 (95 percent C.I.: 1.6 to 2.5), among persons with ADPKD 
observed in the current study were lower than the 6.6 all-cause mean hospital days among 
chronic kidney disease patients reported by Khan et al. (Khan et al. 2002).   
Unadjusted Annual Health Care Expenditures 
Mean annual unadjusted hospital expenditures were more than four times higher 
among individuals with ADPKD ($6,646) as compared to individuals without ADPKD 
($1,484), p<0.05.  Mean annual unadjusted expenditures from nursing homes were also 
six-fold higher for the cohort with ADPKD ($252) as compared to the cohort without 
ADPKD ($41), p<0.05.  Unadjusted mean annual outpatient expenditures were almost 
four times higher among individuals with ADPKD ($12,625) than for individuals without 
ADPKD ($3,225), p<0.05.  Mean annual unadjusted medication expenditures for 
individuals with ADPKD ($3,537) were approximately 2.5 times higher when compared 
to individuals without ADPKD ($1,380), p<0.05.  Mean annual unadjusted total health 
care expenditures among individuals with ADPKD ($23,242) were more than three and 
one-half times as high as for individuals without ADPKD ($6,230), p<0.05. 
Similar to current study findings, where persons with ADPKD had higher health 
care expenditure than persons without ADPKD, prior studies have reported higher health 
care expenditures in persons with chronic kidney disease compared to individuals without 
chronic kidney disease (Smith et al. 2004; Baumeister et al. 2010).  However, differences 
were observed between some types of all-cause health care expenditure among ADPKD 





with chronic kidney disease in general.  All-cause mean annual total health care 
expenditures associated with ADPKD $23,242 (95 percent C.I.: $21,590 to $24,895) was 
lower than the total health care expenditures of $37,330 among individuals with chronic 
kidney disease, reported by London et al. (London et al. 2002).  However, the all-cause 
mean medication expenditures among individuals with ADPKD, $3,537 (95 percent C.I.: 
$3,324 to $3,751), were more than twice the all-cause mean medication expenditures of 
$1,503 among individuals with chronic kidney disease, reported by London and 
colleagues (London et al. 2002). 
London et al. estimated health care expenditures using billed amounts for each 
service whereas in the current study, standard prices were used to calculate health care 
expenditures.  Billed amounts for medical services may differ across regions whereas 
standard prices adjust for geographic variation in provider pricing.  Therefore, differences 
in all-cause health care expenditures between the study by London et al. and the current 
study may be due to the type of cost estimates used to estimate expenditures.   
Incremental Annual Health Care Resource Utilization Associated with ADPKD  
The sample of 7,688 persons used to determine all-cause health care resource 
utilization and expenditures was also used for estimation of incremental resource 
utilization associated with ADPKD.  ADPKD was associated with many more outpatient 
visits as reflected in a mean of 6.9 (0.28), p<0.05 incremental outpatient visits.  Although 
ADPKD was associated with incrementally more hospitalizations, 0.087 (0.011), p<0.05, 





incremental hospital days, 0.68 (0.090), p<0.05.  Emergency room visits were also 
incrementally greater among persons with ADPKD, 0.29 (0.055), p<0.05.   
To our knowledge, no prior study has estimated incremental health care resource 
utilization associated with ADPKD.  However, some prior studies estimated incremental 
health care resource utilization associated with persons with chronic diseases of the 
kidneys (Baumeister et al. 2010; Smith et al. 2004).  Higher resource utilization 
associated with having chronic kidney disease were reported by Smith. et al. and 
Baumeister et al., which was consistent with the current finding of higher resource 
utilization associated with having ADPKD.  Smith et al. reported that persons with stage 
2 chronic kidney disease had 7.5 incremental outpatient visits, those with stage 3 chronic 
kidney disease had 3.5 incremental outpatient visits and those with stage 4 chronic kidney 
disease had 10.2 incremental outpatient visits per year compared to those without chronic 
kidney disease.  In comparison, a mean of 6.9 (0.28), p<0.05 incremental outpatient visits 
associated with ADPKD were estimated in the current study.  Smith et al. also reported 
that persons with stage 2 chronic kidney disease had 0.29 incremental hospitalizations, 
those with stage 3 chronic kidney disease had 0.17 incremental hospitalizations  and 
those with stage 4 chronic kidney disease had 0.70 incremental hospitalizations per year 
when compared to those without chronic disease.  In comparison, estimated mean 
incremental hospitalizations of 0.087 (0.011), p<0.05 associated with ADPKD found in 
the current study, were lower than any of the estimates reported by Smith et al.   
Regression models used by Smith et al. to estimate incremental health care 
resource utilization in chronic kidney disease were adjusted for age and gender only, 





co-morbidity index score, cardiovascular disease, diabetes and geographical region.  
Lower incremental resource utilization estimates in the current study, compared to those 
presented by Smith et al., may be related to adjustment of those risk factors that may have 
inflated resource utilization estimates in the Smith et al. study.  
Baumeister et al. conducted a study in a general population in the city of 
Augsburg in Germany and reported that chronic kidney disease was associated with 3.7 
additional mean annual incremental outpatient visits (Baumeister et al. 2010), which was 
lower than the 6.9 (0.28), p<0.05 mean incremental outpatient visits associated with 
ADPKD in the current study.  However, the study by Baumeister et al. reported higher 
4.6 mean annual incremental hospital days (Baumeister et al. 2010), compared to the 0.68 
mean incremental hospital days found in the current study.  Both, the study by 
Baumeister et al. as well as the current study, used multivariate regression to estimate 
incremental resource utilization adjusted for age, gender and comorbidities.  However, 
Baumeister et al. studied a cohort of patients with chronic kidney disease over a ten-year 
period whereas the current study estimated utilization over a one-year period only, which 
may explain observed differences in incremental resource utilization estimates between 
the two studies.   
The studies by Smith et al. and by Baumeister et al. estimated incremental 
resource utilization associated with chronic kidney diseases regardless of disease etiology 
whereas this current study focused on estimating incremental resource utilization 
associated specifically with ADPKD (Baumeister et al. 2010; Smith et al. 2004).  





previous reports and estimates found in this current study may also be due to differences 
in composition of study samples.       
Incremental Annual Health Care Expenditures Associated with ADPKD  
The same sample of 7,688 persons used to determine incremental health care 
resource utilization was also used for estimation of incremental expenditures associated 
with ADPKD.  The mean incremental total health care expenditure associated with 
ADPKD was $7,917 ($431), p<0.05.  The mean incremental outpatient expenditures 
associated with ADPKD, $4,507 ($181), p<0.05, accounted for the largest incremental 
expenditure.  Hospital expenditures were the second largest incremental expenditure 
associated with ADPKD, $2,385 ($241), p<0.05.  Incremental expenditures associated 
with ADPKD for medication expenditures were $1,456 ($71), p<0.05 and incremental 
emergency room expenditures were $62 ($7), p<0.05.   
Smith et al. estimated incremental health care expenditures associated with each 
stage of chronic kidney disease (Smith et al. 2004).  According to Smith et al., mean 
annual incremental outpatient expenditures associated with stage 2 chronic kidney 
disease was $4,646, associated with stage 3 chronic kidney disease was $3,194, and 
associated with stage 4 chronic kidney disease was $3,549 (Smith et al. 2004).  In 
comparison, mean incremental outpatient expenditures associated with ADPKD in the 
current study were $4,507 ($181), p<0.05.  Smith et al. also reported that mean annual 
incremental total health care expenditures associated with stage 2 chronic kidney disease 
was $22,552, incremental expenditures associated with stage 3 chronic kidney disease 





disease was $22,821 (Smith et al. 2004).  In comparison, the current study estimated a 
lower mean incremental total health care expenditures of $7,917 ($431), p<0.05, 
associated with ADPKD. 
Both, the study by Smith et al. as well as the current study, used standard prices to 
calculate health care expenditures that reflected allowed payments from a single source 
with a consistent payment plan.  However, Smith et al. only adjusted for age and gender 
only whereas in the current study, multivariate regression equations adjusted for age, 
gender, co-morbidity index score, cardiovascular disease, diabetes and geographical 
region.  Lower incremental expenditure estimates in the current study, compared to those 
presented by Smith et al., might be due to adjustment for those risk factors.  Also, the 
study by Smith et al. estimated incremental expenditures associated with chronic kidney 
diseases regardless of disease etiology whereas this current study focused on estimating 
incremental expenditures associated specifically with ADPKD (Smith et al. 2004).  
Therefore, observed differences in incremental resource expenditures estimates between 
the study by Smith et al. and estimates found in this current study may also be due to 
differences in composition of the sample across studies.   
The current study findings indicate that ADPKD is associated with significant 
incremental health care expenditures even after adjusting for age, gender, co-morbidities, 
cardiovascular disease, diabetes and geographical region.   Quantifying the specific 
health care expenditure components such as incremental expenditures from hospitals, 
nursing homes, outpatient visits, emergency room visits and medications provide 





expenditure estimates indicate the potential savings that may be achieved if ADPKD 
were better treated or controlled.   
Sub-Group Analysis by whether Diagnosed with End-Stage Renal Disease 
Among 3,844 persons with ADPKD, 644 had a diagnosis of end-stage renal 
disease and 3,200 persons with ADPKD had not been diagnosed with end-stage renal 
disease.  Significant incremental, mean (standard error) hospitalizations, 0.35 (0.052), 
p<0.05 and hospital days, 2.5 (0.42), p<0.05 were associated with ADPKD in the sub-
group with end-stage renal disease.  There were also significant incremental 
hospitalizations, 0.065 (0.028), p<0.05 and hospital days, 0.50 (0.091), p<0.05 associated 
with ADPKD in the sub-group without end-stage renal disease.  Although the magnitude 
of estimated incremental hospitalizations and hospital days were greater in the sub-group 
with end-stage renal disease as compared to estimates from the model including all 
persons regardless of end-stage renal disease status, ADPKD was still associated with 
significant incremental hospitalizations and hospital days in the sub-group containing 
only persons without end-stage renal disease.  The magnitude of the estimates of 
incremental hospitalizations in the group without end-stage renal disease, 0.065 (0.028), 
p<0.05 were similar to those from the model including everyone regardless of end-stage 
renal disease status, 0.087 (0.011), p<0.05.  The same was true for the magnitude of the 
incremental hospital days estimate among those without end-stage renal disease, 0.50 
(0.091), p<0.05, as compared to that from the model for all individuals regardless of end-





Although the sub-group with end-stage renal disease had several times higher 
incremental outpatient visits 24.0 (1.2), p<0.05 associated with ADPKD as compared to 
the estimates for all individuals with ADPKD regardless of end-stage renal disease status, 
6.9 (0.28), p<0.05; the ADPKD sub-group without end-stage renal disease had mean 
incremental outpatient visits, 4.4 (0.41), p<0.05 close in magnitude to those from the 
inclusive sample.  In contrast, the sub-group analysis revealed that there were not 
significant incremental emergency room visits associated with ADPKD in the sub-group 
with end-stage renal disease, but that the sub-group without end-stage renal disease did 
have significant incremental emergency room visits 0.32 (0.058), p<0.05 associated with 
ADPKD and of similar magnitude to that from the model for all individuals regardless of 
end-stage renal disease status, 0.29 (0.055), p<0.05. 
The ADPKD sub-group with end-stage renal disease had mean incremental total 
expenditures associated with ADPKD $42,547 ($2,102), p<0.05, that were much higher 
than those for the sample including all persons with ADPKD regardless of end-stage 
renal disease status $7,917 ($431), p<0.05.  Although the sub-group without end-stage 
renal disease had lower incremental mean total expenditures $3,053 ($374), p<0.05 
associated with ADPKD than for the group including everyone regardless of end-stage 
renal disease status $7,917 ($431), p<0.05, the incremental expenditures were still large.  
Similar relationships were seen in comparison across the sub-group with end-stage renal 
disease, the sub-group without end-stage renal disease and the overall sample, for 
incremental hospital expenditure $9,430 ($1,179), p<0.05, $1,365 ($207), p<0.05, and 
$2,385 ($241), p<0.05; outpatient expenditures $26,539 ($1,373) p<0.05, $1,247 ($119), 





$824 ($61), p<0.05, and $1,456 ($71), p<0.05 respectively.  However, incremental 
emergency room expenditures associated with ADPKD were of similar magnitude for the 
sub-group with end-stage renal disease $67 ($22), p<0.05, the sub-group without end-
stage renal disease $63 ($8), p<0.05, and the overall group incorporating all individuals 
regardless of end-stage renal disease status $62 ($7), p<0.05. 
Prior studies have found declining renal function is associated with increased 
risks of adverse outcomes including health care resource utilization and health care 
expenditures (Go et al. 2004; Smith et al. 2004; Lentine et al. 2010).  Mean annual all-
cause total health care expenditures reported by Lentine et al. were $26,521 at early 
stages of renal function decline among individuals with ADPKD and all-cause 
expenditures rose to $140,139 when ADPKD patients reached end-stage renal disease 
(Lentine et al. 2010).  The current study found that mean all-cause health care 
expenditures were higher for the ADPKD sub-group with end-stage renal disease $78,451 
(95 percent C.I.: $71,168 to $85,733) than for the ADPKD sub-group without end-stage 
renal disease $12,131 (95 percent C.I.: $11,174 to $13,089).  The current study also 
found that  mean incremental total health care expenditures associated with ADPKD were 
higher for the ADPKD sub-group with end-stage renal disease $42,547 ($2,102) than for 
the ADPKD sub-group without end-stage renal disease $3,053 ($374).   
Although both, the study by Lentine et al. as well as the current study, reported 
higher all-cause health care expenditures among ADPKD patients who reached advanced 
stages of renal disease, compared to those ADPKD patients who had not reached end-
stage renal disease, expenditure estimates in the current study differed from expenditures 





and medications from charges reported on claims paid by a large national health 
insurance provider (Lentine et al. 2010), the current study used standard prices that 
reflected allowed payments from a single source with a consistent payment plan.   
A diagnosis of ADPKD without end-stage renal disease was associated with 
considerable incremental inpatient expenditures, outpatient expenditures and medication 
expenditures, and total health care expenditures.  The finding that the economic burden of 
ADPKD was present even before end-stage renal disease was reached indicates that early 
intervention in treating or controlling ADPKD may offer significant savings.   
Study Limitations 
A limitation of this study was that ICD-9-CM codes were used to identify 
individuals with ADPKD.  Also the comorbidities used for the Charlson Comorbidity 
Index were identified using ICD-9-CM codes.  Use of diagnostic codes in claims to 
identify diagnosis is known to be imperfect due to variations in coding (Romano and 
Mark 1994).  However, the set of codes used in this study to identify ADPKD have been 
utilized in prior studies (Lentine et al. 2010; Perrone et al. 2005).  Since the database used 
for the study consisted of claims information from privately insured individuals, this 
study is generalizable only to the privately insured population.  However, when compared 
to the only other estimate of U.S. prevalence of ADPKD that was limited to one county in 







Prevalence of ADPKD in a private-pay population was one in 1,786 persons or 
560 cases per million population.  The study findings indicate that ADPKD is associated 
with significant incremental health care resource utilization and incremental health care 
expenditures even after adjusting for age, gender, co-morbidities, cardiovascular disease, 
diabetes and geographical region.  Incremental resource utilization (standard error) from 
outpatient visits were large, 6.9 (0.28).  Significant incremental resource utilization 
associated with ADPKD for hospitalizations, 0.087 (0.011), hospital days, 0.68 (0.090) 
and emergency room visits, 0.29 (0.055) was also found.  Considerable incremental 
expenditures from hospital expenditures $2,385 ($241), incremental medication 
expenditures $1,456 ($71), and substantially high incremental outpatient expenditures, 
$4,507 ($181) associated with ADPKD were also observed.   
Sub-group analysis of incremental resource utilization and expenditures by 
whether diagnosed with end-stage renal disease revealed substantially higher incremental 
burden for patients with ADPKD and diagnosed with end-stage renal disease.  However, 
a diagnosis of ADPKD without end-stage renal disease was associated with significant 
incremental inpatient expenditures, outpatient expenditures and medication expenditures.  
These findings indicate that considerable illness burden is associated with ADPKD even 
before patients reach end-stage renal disease.   
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Table A1. Unadjusted Annual Health Care Resource Utilization among Persons with ADPKD by Age 
 ____________________________________________________________________________________________________________ 
  Under 35 35 to 44 45 to 54 55 to 64 65 and over 
  (n=621) (n=748) (n=1,043) (n=1,059) (n=373) 
 ____________ ___________   ____________  __________   ___________ 
  Mean Mean Mean Mean Mean  
Utilization Category (95% CI) (95% CI) (95% CI) (95% CI) (95% CI)  
 ____________________________________________________________________________________________________________ 
Hospitalizations 0.20 0.16 0.25 0.26 0.34 
  (0.16 to 0.25) (0.11 to 0.22) (0.20 to 0.30) (0.21 to 0.30) (0.27 to 0.40) 
    
Hospital days 2.1 1.2 1.6 2.3 4.3 
  (0.87 to 3.3) (0.20 to 2.1) (1.0 to 2.2) (1.4 to 3.2) (1.8 to 6.9) 
 
Nursing home confinements 0 0.0013 0.0048 0.016 0.059 
   (-0.0013 to 0.0040) (0.00059 to 0.0090) (0.0072 to 0.025) (0.030 to 0.088) 
 
Nursing home days 0 0.057 0.12 0.44 1.7 
   (-0.055 to 0.17) (-0.029 to 0.28) (0.14 to 0.74) (0.48 to 2.9) 
 
Outpatient visits 13.1 17.8 21.3 23.4 27.5 
  (11.9 to 14.3) (15.8 to 19.7) (19.8 to 22.9) (23.8 to 26.9) (25.2 to 30.3) 
 
Emergency room visits 1.1 1.0 0.99 1.1 0.91 








Table A2. Unadjusted Annual Health Care Resource Utilization among Persons with 
ADPKD by Gender 
 ______________________________________________________________________  
   Female Male 
   (N=2,047) (N=1,797) 
  ____________________   ____________________  
   Mean Mean 
Utilization Category (95% CI) (95% CI) 
 ______________________________________________________________________  
Hospitalizations 0.23 0.24  
   (0.20 to 0.26) (0.21 to 0.28) 
 
Hospital days 1.9 2.2  
   (1.3 to 2.5) (1.5 to 2.9) 
  
Nursing home confinements 0.0092 0.014  
   (0.0047 to 0.014) (0.0077 to 0.021) 
  
Nursing home days 0.37 0.29 
   (0.12 to 0.62) (0.12 to 0.45) 
  
Outpatient visits 21.8 20.2 
   (20.7 to 22.9) (19.1 to 21.4) 
  
Emergency room visits 1.1 0.96 
   (0.99 to 1.3) (0.82 to 1.1) 





Table A3. Unadjusted Annual Health Care Resource Utilization among Persons with 
ADPKD by ADPKD Complication – Liver Cystsa 
 ______________________________________________________________________  
   No Liver Cysts Liver Cysts 
   (n=3,747) (n=97) 
  ____________________   ____________________  
   Mean Mean 
Utilization Category (95% CI) (95% CI) 
 ______________________________________________________________________  
Hospitalizations 0.22 0.70  
   (0.20 to 0.25) (0.43 to 0.96) 
 
Hospital days 1.9 6.5 
   (1.5 to 2.4) (1.3 to 11.7) 
  
Nursing home confinements 0.011 0.010 
   (0.0077 to 0.015) (-0.010 to 0.030) 
  
Nursing home days 0.33 0.17 
   (0.18 to 0.49) (-0.17 to 0.52) 
  
Outpatient visits 20.7 32.7 
   (20.0 to 21.6) (26.7 to 38.7) 
  
Emergency room visits 1.0 1.2 
   (0.95 to 1.2) (0.51 to 1.9) 
 ______________________________________________________________________  






Table A4. Unadjusted Annual Health Care Resource Utilization among Persons with 
ADPKD by ADPKD Complication – Kidney Stonesa 
 ______________________________________________________________________  
   No Kidney Stones Kidney Stones 
   (n=3,532) (n=312) 
  ____________________   ____________________  
   Mean Mean  
Utilization Category (95% CI) (95% CI) 
 ______________________________________________________________________  
Hospitalizations 0.22 0.44  
   (0.20 to 0.24) (0.31 to 0.57) 
 
Hospital days 1.9 3.4  
   (1.5 to 2.4) (1.3 to 5.5) 
  
Nursing home confinements 0.011 0.0096 
   (0.0076 to 0.016) (-0.0012 to 0.020) 
  
Nursing home days 0.35 0.099 
   (0.18 to 0.52) (-0.042 to 0.24) 
  
Outpatient visits 20.8 24.4 
   (19.9 to 21.6) (22.2 to 26.7) 
  
Emergency room visits 1.0 1.7 
   (0.90 to 1.1) (1.2 to 2.1) 
 ______________________________________________________________________  






Table A5. Unadjusted Annual Health Care Resource Utilization among Persons with 
ADPKD by ADPKD Complication – Urinary Tract Infection (UTI)a 
 ______________________________________________________________________  
   No UTI UTI 
   (n=3,238) (n=606) 
  ____________________   ____________________  
   Mean Mean 
Utilization Category (95% CI) (95% CI) 
 ______________________________________________________________________  
Hospitalizations 0.18 0.54  
   (0.16 to 0.20) (0.44 to 0.64) 
 
Hospital days 1.6 4.7 
   (1.1 to 2.0) (3.0 to 6.4) 
  
Nursing home confinements 0.0074 0.034 
   (0.0040 to 0.010) (0.017 to 0.051) 
  
Nursing home days 0.23 0.84 
   (0.091 to 0.38) (0.28 to 1.4) 
  
Outpatient visits 19.3 30.5 
   (18.5 to 20.1) (28.3 to 32.7) 
  
Emergency room visits 1.0 1.5 
   (0.87 to 1.1) (1.2 to 1.7) 
 ______________________________________________________________________  






Table A6. Unadjusted Annual Health Care Resource Utilization among Persons with 
ADPKD by ADPKD Complication – Cerebral Aneurysma 
 ______________________________________________________________________  
   No Cerebral Aneurysm Cerebral Aneurysm 
   (n=3,808) (n=36) 
  ____________________   ____________________  
   Mean Mean  
Utilization Category (95% CI) (95% CI)  
 ______________________________________________________________________  
Hospitalizations 0.23 1.0  
   (0.21 to 0.25) (0.53 to 1.5) 
 
Hospital days 2.0 7.7 
   (1.5 to 2.5) (1.2 to 14.2) 
  
Nursing home confinements 0.011 0 
   (0.0078 to 0.015)  
  
Nursing home days 0.33 0 
   (0.18 to 0.49)  
  
Outpatient visits 20.9 33.5 
   (20.1 to 21.7) (21.8 to 45.1) 
  
Emergency room visits 1.0 1.4 
   (0.95 to 1.2) (0.057 to 2.8) 
 ______________________________________________________________________  






Table A7. Unadjusted Annual Health Care Resource Utilization among Persons with 
ADPKD by ADPKD Complication – Any Complicationa 
 ______________________________________________________________________  
             At Least One 
   No Complication       ADPKD Complication 
   (n=2,934) (n=910) 
  ____________________   ____________________  
   Mean Mean 
Utilization Category (95% CI) (95% CI) 
 ______________________________________________________________________  
Hospitalizations 0.16 0.48  
   (0.14 to 0.18) (0.40 to 0.56) 
 
Hospital days 1.5 4.0 
   (0.99 to 1.9) (2.7 to 5.2) 
  
Nursing home confinements 0.0078 0.024 
   (0.0041 to 0.011) (0.012 to 0.035) 
  
Nursing home days 0.26 0.57 
   (0.097 to 0.42) (0.19 to 0.95) 
  
Outpatient visits 18.8 28.4 
   (17.9 to 19.7) (26.7 to 30.1) 
  
Emergency room visits 0.94 1.4 
   (0.83 to 1.0) (1.2 to 1.7) 
 ______________________________________________________________________  
a A diagnosis for any one of four ADPKD complications including liver cysts, kidney 
stones, urinary tract infection or cerebral aneurysm during the study period from April 1, 





Table A8. Unadjusted Annual Health Care Resource Utilization among Persons with ADPKD by Number of ADPKD Complicationsa 
 ____________________________________________________________________________________________________________ 
  0 1 2 3 4 
  (n=2,934) (n=776) (n=127) (n=7) (n=0) 
 ____________ ___________   ____________  __________   ___________ 
  Mean Mean Mean Mean Mean 
Utilization Category (95% CI) (95% CI) (95% CI) (95% CI) (95% CI)  
 ____________________________________________________________________________________________________________ 
Hospitalizations 0.16 0.41 0.78 2.6 0 
  (0.14 to 0.18) (0.34 to 0.49) (0.57 to 0.99) (-0.14 to 5.3)  
    
Hospital days 1.5 3.2 8.0 12.8 0 
  (0.99 to 1.9) (2.0 to 4.4) (2.6 to 13.4) (-2.4 to 28.1)  
 
Nursing home confinements 0.0078 0.024 0.023 0 0 
  (0.0041 to 0.011) (0.011 to 0.037) (-0.0031 to 0.050)   
 
Nursing home days 0.26 0.62 0.28 0 0 
  (0.097 to 0.42) (0.18 to 1.1) (-0.11 to 0.67)   
 
Outpatient visits 18.8 27.8 30.2 58.6 0 
  (17.9 to 19.7) (25.9 to 29.7) (26.6 to 33.7) (9.2 to 108.0)  
 
Emergency room visits 0.94 1.4 1.8 2.6 0 
  (0.83 to 1.0) (1.1 to 1.6) (1.1 to 2.5) (0.65 to 4.5)   
 ____________________________________________________________________________________________________________ 
aNumber of ADPKD complications, including liver cysts, kidney stones, urinary tract infection or cerebral aneurysm, ranging from 0 













Table B1. Unadjusted Annual Health Care Expenditures in Dollars among Persons with ADPKD by Age 
 ____________________________________________________________________________________________________________ 
  Under 35 35 to 44 45 to 54 55 to 64 65 and over 
  (n=621) (n=748) (n=1,043) (n=1,059) (n=373) 
 ____________ ____________  ____________ ____________ ____________ 
  Mean Mean Mean Mean Mean  
Expenditure Category (95% CI) (95% CI) (95% CI) (95% CI) (95% CI)  
 ____________________________________________________________________________________________________________ 
Inpatient  6,152 2,991 7,116 8,126 9,290  
expenditures (2,781 to 9,522) (1,840 to 4,141) (5,275 to 8,957) (6,244 to 10,008) (6,797 to 11,782) 
 
Nursing home  0 40 106 385 1,128 
expenditures  (-38 to 119) (-31 to 243) (61 to 709) (391 to 1,865) 
   
Outpatient  4,583 8,978 14,605 17,300 14,525 
expenditures (3,700 to 5,465) (6,964 to 10,992) (12,214 to 16,996) (14,899 to 19,701) (11,153 to 17,896) 
 
Emergency room  209 171 201 164 129 
expenditures (167 to 251) (142 to 201) (153 to 249) (139 to 189) (85 to 172) 
     
Medication  1,989 2,236 3,700 4,774 4,759 
expenditures (1,326 to 2,652) (1,837 to 2,636) (3,313 to 4,087) (4,363 to 5,186) (4,184 to 5,333) 
 
Total health care  12,933 14,417 25,729 30,751 29,830 








Table B2. Unadjusted Annual Health Care Expenditures in Dollars among Persons with 
ADPKD by Gender 
 ______________________________________________________________________  
   Female Make 
   (n=2,047) (n=1,797) 
  ____________________   ____________________  
   Mean Mean 
Expenditure Category (95% CI) (95% CI) 
 ______________________________________________________________________  
Inpatient expenditures 6,058 7,317  
   (4,747 to 7,370) (5,904 to 8,730) 
 
Nursing home expenditures 218 290 
   (83 to 353) (81 to 500) 
 
Outpatient expenditures 12,206 13,104  
   (10,786 to 13,626) (11,467 to 14,740)  
  
Emergency room expenditures 201 155 
   (172 to 229) (136 to 174) 
 
Medication expenditures 3,185 3,939 
   (2,902 to 3,486) (3,616 to 4,262) 
 
Total health care expenditures 21,869 24,806  






Table B3. Unadjusted Annual Health Care Expenditures in Dollars among Persons with 
ADPKD by ADPKD Complication – Liver Cystsa 
 ______________________________________________________________________  
   No Liver Cysts Liver Cysts 
   (n=3,747) (n=97) 
  ____________________   ____________________  
   Mean Mean 
Expenditure Category (95% CI) (95% CI) 
 ______________________________________________________________________  
Inpatient expenditures 6,247 22,095  
   (5,315 to 7,178) (9,790 to 34,400) 
 
Nursing home expenditures 256 108 
   (131 to 380) (-107 to 324) 
 
Outpatient expenditures 12,339 23,697  
   (11,275 to 13,403) (12,490 to 34,903)  
  
Emergency room expenditures 178 232 
   (160 to 196) (129 to 334) 
 
Medication expenditures 3,490 5,363 
   (3,274 to 3,707) (4,080 to 6,646) 
 
Total health care expenditures 22,511 51,496  
   (20,889 to 24,132) (32,894 to 70,098)  
 ______________________________________________________________________  





Table B4. Unadjusted Annual Health Care Expenditures in Dollars among Persons with 
ADPKD by ADPKD Complication – Kidney Stonesa 
 ______________________________________________________________________  
   No Kidney Stones Kidney Stones 
   (n=3,532) (n=312) 
  ____________________   ____________________  
   Mean Mean  
Expenditure Category (95% CI) (95% CI) 
 ______________________________________________________________________  
Inpatient expenditures 6,345 10,058  
   (5,340 to 7,351) (6,796 to 13,319) 
 
Nursing home expenditures 265 103 
   (134 to 397) (-38 to 245) 
 
Outpatient expenditures 12,610 12,803  
   (11,466 to 13,754) (9,981 to 15,625)  
  
Emergency room expenditures 160 394 
   (146 to 175) (254 to 534) 
 
Medication expenditures 3,563 3,253 
   (3,340 to 3,785) (2,479 to 4,028) 
 
Total health care expenditures 22,944 26,612  
   (21,202 to 24,687) (21,564 to 31,660)  
 ______________________________________________________________________  






Table B5. Unadjusted Annual Health Care Expenditures in Dollars among Persons with 
ADPKD by ADPKD Complication – Urinary Tract Infection (UTI)a 
 ______________________________________________________________________  
   No UTI UTI 
   (n=3,238) (n=606) 
  ____________________   ____________________  
   Mean Mean 
Expenditure Category (95% CI) (95% CI) 
 ______________________________________________________________________  
Inpatient expenditures 5,298 13,851 
   (4,342 to 6,254) (10,572 to 17,130) 
 
Nursing home expenditures 160 742 
   (65 to 255) (163 to 1,322) 
 
Outpatient expenditures 11,794 17,068  
   (10,637 to 12,952) (14,211 to 19,924)  
  
Emergency room expenditures 152 325 
   (137 to 167) (248 to 402) 
 
Medication expenditures 3,370 4,433 
   (3,142 to 3,598) (3,847 to 5,019) 
 
Total health care expenditures 20,776 36,420  
   (19,093 to 22,479) (31,332 to 41,507)  
 ______________________________________________________________________  
a A diagnosis of urinary tract infection during the study period from April 1, 2011 to 





Table B6. Unadjusted Annual Health Care Expenditures in Dollars among Persons with 
ADPKD by ADPKD Complication – Cerebral Aneurysma 
 ______________________________________________________________________  
   No Cerebral Aneurysm Cerebral Aneurysm 
   (n=3,808) (n=36) 
  ____________________   ____________________  
   Mean Mean  
Expenditure Category (95% CI) (95% CI)  
 ______________________________________________________________________  
Inpatient expenditures 6,308 42,474  
   (5,373 to 7,243) (16,233 to 68,714) 
 
Nursing home expenditures 254 0 
   (132 to 377)  
 
Outpatient expenditures 12,416 34,839  
   (11,354 to 13,477) (10,974 to 58,703)  
  
Emergency room expenditures 178 284 
   (160 to 196) (118 to 450) 
 
Medication expenditures 3,544 2,863 
   (3,329 to 3,759) (1,610 to 4,116) 
 
Total health care expenditures 22,701 80,459  
   (21,080 to 24,322) (41,355 to 119,564)  
 ______________________________________________________________________  






Table B7. Unadjusted Annual Health Care Expenditures in Dollars among Persons with 
ADPKD by ADPKD Complication – Any Complicationa 
 ______________________________________________________________________  
             At Least One 
   No Complication       ADPKD Complication 
   (n=2,934) (n=910) 
  ____________________   ____________________  
   Mean Mean 
Expenditure Category (95% CI) (95% CI) 
 ______________________________________________________________________  
Inpatient expenditures 4,820 12,535 
   (3,845 to 5,796) (9,999 to 15,071) 
 
Nursing home expenditures 174 504 
   (69 to 278) (118 to 891) 
 
Outpatient expenditures 11,400 16,578  
   (10,209 to 12,591) (14,165 to 18,991)  
  
Emergency room expenditures 142 298 
   (127 to 158) (243 to 353) 
 
Medication expenditures 3,377 4,055 
   (3,138 to 3,616) (3,585 to 4,526) 
 
Total health care expenditures 19,914 33,972  
   (18,171 to 21,657) (29,901 to 38,042)  
 ______________________________________________________________________  
a A diagnosis for any one of four ADPKD complications including liver cysts, kidney 
stones, urinary tract infection or cerebral aneurysm during the study period from April 1, 





Table B8. Unadjusted Annual Health Care Expenditures in Dollars among Persons with ADPKD by Number of ADPKD 
Complicationsa 
 ____________________________________________________________________________________________________________ 
  0 1 2 3 4 
  (n=2,934) (n=776) (n=127) (n=7) (n=0) 
 ____________ ____________  ____________ ____________ ____________ 
  Mean Mean Mean Mean Mean 
Expenditure Category (95% CI) (95% CI) (95% CI) (95% CI) (95% CI)  
 ____________________________________________________________________________________________________________ 
Inpatient 4,820 10,316 23,666 56,534 0  
expenditures (3,845 to 5,796) (7,926 to 12,707) (13,359 to 33,972) (981 to 112,097)  
 
Nursing home 174 549 261 0 0 
expenditures (69 to 278) (99 to 999) (-95 to 618)   
   
Outpatient 11,400 16,433 14,668 67,251 0 
expenditures (10,209 to 12,591) (13,769 to 19,098) (10,607 to 18,729) (-22,748 to 152,249)  
 
Emergency room 142 250 571 652 0 
expenditures (127 to 158) (213 to 286) (249 to 894) (-47 to 1,353)  
     
Medication 3,377 4,022 3,969 9,306 0 
expeditures (3,138 to 3,616) (3,498 to 4,547) (2,985 to 4,952) (1,976 to 16,637)  
 
Total health care 19,914 31,572 43,136 133,744 0 
expenditures (18,171 to 21,657) (27,359 to 35,785) (30,980 to 55,292) (14,296 to 253,191)  
 ____________________________________________________________________________________________________________ 
aNumber of ADPKD complications, including liver cysts, kidney stones, urinary tract infection or cerebral aneurysm, ranging from 0 
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